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Atopic dermatitis (AD) is a chronic disease, the prevalence of which has been rising in 
Western society and now affects more than 1 in 5 people. Both genetic factors and abnormal 
immune responses are known to contribute to the onset and persistence of AD. The filaggrin 
gene is mutated in around 40% of AD patients. This contributes to the formation of skin 
barrier against environment, but it has also been associated with immunological abnormalities. 
AD improves markedly on exposure to UV light and this is used to treat severe AD, yet the 
mechanism of action remains elusive. UV prevents excess immune cells infiltrating skin and 
also induces cell death of the immune cells that are already present in lesional AD skin. 
Besides its direct effect on immune cells, UV increases vitamin D levels and vitamin D level 
has been shown to be low in children with severe AD. UV also converts trans-urocanic acid, 
which is the breakdown product of filaggrin, to cis-urocanic acid (cis-UCA). This suppresses 
induction of allergic responses to contact sensitizers. UV releases NO, which also affects 
immune cells. Vitamin D can reduce inflammation by increasing a type of immune cell called 
T regulatory cells (Tregs). The biological function of vitamin D is mediated by vitamin D 
receptor (VDR). All agents are induced by UV although the relative importance of each is not 
understood, nor is their interaction. Therefore, I investigated the effect of NO and cis-UCA on 
immune cells derived from peripheral blood from healthy volunteers. I also investigated the 
correlation between plasma concentration of 25(OH) vitamin D and nitrate, FLG genotype, 
circulating Tregs and clinical efficacy of NB-UVB phototherapy. 
 
Results showed that NO directly promoted the generation of Tregs with enhanced capacity to 
migrate to the skin. The NO-induced Tregs modulated immune response through membrane 
bound TGFβ and PD-1/PD-L1 but not CTLA-4. Cis-UCA might promote inflammation by 
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decreasing Tregs and VDR expression. Cis-UCA might also modulate inflammation by 
inhibiting CD4+T cell migration, enhancing immune suppressive cytokine secretion, 
decreasing CD4+T cell proliferation, inhibiting cell signalling pathway and promoting the 
generation of Tregs indirectly. Results generated from the clinical study suggested that 
although circulating 25 (OH) vitamin D concentration was significantly increased after NB-
UVB phototherapy, the change of circulating 25 (OH) vitamin D concentration did not 
correlate with disease improvement. This suggested that plasma 25 (OH) vitamin D 
concentration could not be used as biomarker to predict clinical efficacy of NB-UVB 
phototherapy. Changes of plasma nitrate concentration and FLG genotype could also not be 
used as biomarker for this purpose. The expression of markers reflecting T cell activation and 
migration were decreased after treatment. Their importance in determining clinical responses 
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Atopic dermatitis (AD) is a common, chronic relapsing inflammatory skin disease associated 
with cutaneous hyper-reactivity to environmental triggers that are innocuous to normal non-
atopic individuals. AD affects 10% to 15% of children and 2% to 10% of adults in 
industrialized countries. There has been increasing interest in this disease triggered by its 
increasing prevalence in western societies and its contribution to the increasing health care 
costs. Yet, the underlying pathophysiologic and genetic mechanisms leading to the 
manifestation of AD are not clear. AD results from a complex interplay between 
environmental triggers, susceptibility genes including mutations in the keratinocyte protein 
filaggrin and altered immune responses resulting in allergic CD4+ T cell (Th2) immunity to 
epidermally encountered antigens. Regulatory T cells (Tregs) play an important role in 
controlling responsiveness to self-antigens and preventing autoimmune diseases, as well as in 
limiting inflammatory responses during inflammation and infection. Currently, studies 
investigating the number and function of Tregs in patients with AD have shown controversial 
results.  
 
It has been long established that symptoms of AD improve on exposure to sunlight. 
Narrowband UVB (NB-UVB) phototherapy is a common treatment modality for a variety of 
skin diseases. Considering the adverse effects for systemic treatment for severe adult AD, 
phototherapy, especially NB-UVB phototherapy may be a more practical long-term treatment. 
However, approximately 50% of patients over an 8-week treatment course do not improve 
after NB-UVB phototherapy. Therefore, it is important to identify characteristics of AD 
patients to determine whether they will respond to phototherapy and to avoid adverse effects 




UVB exposure has also been associated with induction of Tregs in mice and increasing their 
numbers and/or functional capacity may offer benefit to patients with chronic AD.  Active 
vitamin D (1,25(OH)2D3), one of the factors induced by UV-B radiation induces Tregs and is 
suggested to contribute to the suppressive effect of NB-UVB phototherapy. However, UV 
radiation could also have beneficial effects through other pathways known to affect 
immunoregulation. UVB exposure upregulates production of nitric oxide (NO) in the skin 
which also affects immune cell function. The protein filaggrin is broken down in 
differentiating keratinocytes to form the natural moisturizer of the skin. The gene encoding 
filaggrin (FLG) has been shown to be a major predisposing factor for AD. A key breakdown 
product is urocanic acid (UCA) which also acts as a natural sunscreen and undergoes trans-cis 
isomerisation on exposure to UV-B. Cis-UCA is known to modulate immune responses, 
however, the mechanisms of its action remain elusive. The production of all three compounds, 
vitamin D, cis-UCA and NO might all increase in the circulation of patients undergoing UVB 
phototherapy. While the immunomodulatory effect of Vitamin D is well described, cis-UCA 
and NO may also affect the behaviour of T lymphocytes systemically. Therefore, I 
investigated the effect of NO and cis-UCA on the phenotype and function of CD4+T cells and 
monocyte-derived dendritic cells (Mo-DCs) derived from peripheral blood mononuclear cells 
(PBMCs) from healthy volunteers. I also investigated the correlation between plasma 
concentration of 25(OH) vitamin D and nitrate, FLG genotype, circulating Tregs and clinical 
efficacy of NB-UVB phototherapy.  
 
My results showed that NO did not affect the phenotype of human mo-DCs and directly 
affected peripheral CD4+ T cells by inducing functional CD25+Foxp3+CD127-Tregs from 
CD4+CD25lo/- effector T cells. Moreover, NO increased expression of the of skin homing 
marker CLA on these Tregs, suggesting an increased ability of NO-induced Tregs to migrate 
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to the skin. These NO-induced CD25+Foxp3+CD127-Tregs had immunosuppressive 
functions and inhibited autologous CD4+ T cell proliferation. Cytokines, at least IL-10, 
secreted by NO-treated CD4+ T cells were not sufficient for the suppressive function of NO-
induced Foxp3+Tregs. The immune regulatory function of NO-induced Fopx3+Tregs 
required cell-cell contact and was mediated by membrane bound TGFβ and PD-1/PD-L1 but 
not CTLA-4.  
 
Results also showed that cis-UCA might have both pro- and anti-inflammatory effects. Cis-
UCA significantly decreased the proportion of CD25hi Foxp3+ cells from activated CD4+ T 
cells. It also decreased the expression of vitamin D receptor in CD4+ T cells which may 
interfere with the immune regulatory function of vitamin D. These results suggested that there 
might be a fine balance between UV-induced anti-inflammatory molecules’ effect on CD4+ T 
cells. However, Cis-UCA also modulated CD4+ T cell directly by decreasing CD4+ T cell 
proliferation, decreasing phosphorylation of ERK after TCR activation, enhancing immune 
suppressive cytokines secretion, and inhibiting the percentage of CLA+CD4+T cells 
suggesting a decreased ability to migrate to the skin, . Cis-UCA also affected the phenotype 
and function of antigen presenting cells by decreasing the expression of HLA-DR, CD86 and 
CD40 on immature mo-DCs, which led to increased proportion of CD25+Foxp3+CD127- T 
cells when co-cultured with allogenic CD4+ T cells.  
 
Results generated from the clinical study in which all 29 patients got better after phototherapy 
suggested although circulating 25 (OH) vitamin D concentration was significantly increased 
after NB-UVB phototherapy, the change of circulating 25 (OH) vitamin D concentration did 
not correlate with disease improvement. This suggests that vitamin D is not the only pathway 
involved and that other molecules contribute to UVB-induced immune-regulation. The data 
XX 
 
also show that of the levels of circulating nitrate and the FLG genotype did not correlate with 
improvement / change with phototherapy. However, the expression of CD69 and CLA on 
circulating CD4+ T cells was decreased after treatment suggesting that UVB affected T cell 
activation and migration to the skin, and their importance in determining clinical responses 
requires further investigation.               
 
Taken together, the results from my study provide evidence that vitamin D is not the only 
molecule responsible for the beneficial effect of NB-UVB phototherapy. NO and cis-UCA 
may down-regulate immune responses by affecting human peripheral CD4+ T cells and mo-
DCs phenotype and function. A further understanding of the effect of NO and cis-UCA on 
skin resident immune cells will provide more insights for narrowing NB-UVB phototherapy 

















AD atopic dermatitis 
AF700 AlexaFluor700 
AMP antimicrobial peptide 
APC antigen presenting cells 
Br-cGMP 8-Bromoguanosine 3′,5′-cyclic monophosphate sodium salt 
cDNA Complementary DNA 
cGMP cyclic guanosine monophosphate 
CHS Contact hypersensitivity 
CLA cutaneous lymphocyte-associated antigen 
CTLA-4 cytotoxic T cell associated antigen-4 
CTLs cytotoxic T lymphocytes 
DC dendritic cell 
DTH delayed type hypersensitivity 
Ebi3 Epstein-Barr-virus-induced gene 3 
ECL enhanced chemiluminescence 
FcεRI high affinity receptor for IgE 
GITR glucocorticoid-induced TNF receptor family-related 
gene/protein 
HDM house dust mite 
HNO2 nitrous acid 
ICAM-3 intercellular adhesion molecule-3 
IDEC inflammatory dendritic epidermal cells 
IDO Indoleamine 2, 3-dioxygenase 
XXII 
 
IFN-γ interferon gamma 
IL-2 Interleukin 2 
IL-2R Interleukin 2 Receptor 
IL-12α interleukin-12 alpha 
IPEX immunodysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome 
iTreg induced regulatory T cell 
LAP latency-associated peptide 
LC Langerhans cell 
L-NMMA NG-monomethyl-L-arginine acetate 
LAP latency-associated peptide 
MACS magnetic activated cell sorting 
MFI mean fluoresce intensity 
MLR mixed lymphocyte reaction 
Mo-DC monocyte-derived dendritic cell 
NB-UVB Narrow band UVB 
NK cells natural killer cells 
NMF natural moisturizing factors 
N-nitrosamine RNNOs 
NO nitric oxide 
NOC-18 3,3-Bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene 
nTreg Natural regulatory T cell 
ODQ 1-H-oxodiazolo-[1,2,4]- [4,3-a]quinoxalin-1-one 
PAR proteinase-activated receptor 
XXIII 
 
PBMC peripheral blood mononuclear cell 
pCPA 4-Chloro-DL-phenylalanine 
PD-1 Programmed death-1 
Poly I/C Polyinosinic-polycytidylic 
PVDF Polyvinyl difluoride 
RANK receptor activator of NF- κB 
RANKL receptor activator of NF- κB ligand 
RIPA Radio Immunoprecipitation Assay  
sGC Soluble guanylyl cyclase  
RSNO S-nitrosothiols 
SPF sun protection factor 
TCR T cell receptor 
Th2 T helper type 2 cell 




regulatory T cell 
toll like receptor 
T helper type 1 cell 
TSLP thymic stromal lymphopoietin 
UCA urocanic acid 
VCAM-1 vascular cell adhesion molecule-1 







Chapter 1 Introduction 
 
Atopic dermatitis (AD) is the most common chronic relapsing inflammatory skin disease 
associated with cutaneous hyper-reactivity to environmental triggers that are innocuous to 
non-atopic individuals (Leung et al., 2004).  The majority of cases, at least 60%, arise within 
the first year of life (Bieber, 2012). The prevalence of AD has increased 2-3 times during past 
three decades and affects 10–20% in children and up to 5% in adults in industrialized 
countries (Boguniewicz and Leung, 2011). In the past few years, studies have shown that 
there is strong association between mental health and AD (Leung and Guttman-Yassky, 2014). 
Effective management of AD contributes to the well-being of patients and their family‘s 
quality of life. There has been increasing interest in this disease triggered by its increasing 
prevalence in western societies and its contribution to the increasing health care costs.  
The symptoms of the majority of AD patients improve with first-line topical treatment 
including emollients, corticosteroids, calcineurin inhibitors and environmental trigger 
avoidance. Phototherapy is recommended in both acute and chronic AD after failure of first-
line treatment. Phototherapy can also be used as maintenance therapy and is indicated for 
patients with chronic disease. Compared with other phototherapies, narrowband UVB therapy 
(NB-UVB) is generally the most commonly recommended light treatment considering its low 
risk profile, relative efficacy and availability (Eichenfield et al., 2014). However, in 
comparison with psoriasis, which is still the most frequent indication for NB-UVB 
phototherapy, a reasonable number of AD patients do not respond to the treatment. In general, 
patients with AD do less reliably respond to phototherapy. Therefore, it is important to 
identify the molecular mechanisms responsible for the beneficial effects of NB-UVB, and 




respond to phototherapy. These characteristics including genotype, biomarkers reflecting 
immune polarization and the clinical phenotype, can be used in further clinical study design 
and drug development to use existing or novel therapies to patients that most likely to benefit 
from a mechanism-based treatment. 
 
1.1 Atopic dermatitis 
1.1.1 Normal structure and immune responses in skin 
Human skin as the primary interface between the body and the environment has two main 
compartments: the epidermis and the dermis as shown in Fig 1.1. The skin acts as an effective 
physical barrier against pathogens and exerts critical immunological functions during 
homeostasis and in various pathological conditions. The epidermis contains four layers 
including stratum basale, stratum spinosum, stratum granulosum and stratum corneum. 
Besides keratinocytes and melanocytes, immune cells such as Langerhans cells (LCs) which 
are the major antigen presenting cells in epidermis and mainly CD8+ T cells can be found in 
the epidermis. Dermis is less densely packed with cells comp ared to epidermis and is 
composed of extracellular matrix produced by fibroblasts. Some important immune cells have 
been found in dermis including various dendritic cell (DC) subsets, CD4+ T cells, 






Fig 1.1 Normal skin structure and immune cell subsets in the epidermis and the dermis. 
 
1.1.2 Clinical features and phenotypes of AD 
AD used to be delineated as two forms: an extrinsic form associated with high IgE 
concentration involving 70–80% of the patients, and an intrinsic form without IgE-mediated 
sensitization involving 20–30% of the patients. However, it is reported that intrinsic patients 
had detectable serum IgE to autoantigens in the skin and may also have IgE specific to 
microbial or fungi antigens which are not routinely measured (Novak et al., 2003). Recent 
studies suggest that AD is not a single disease and should be categorized based on gene 




AD is a major risk factor for developing food allergy, allergic rhinitis, or asthma later in life 
(Spergel, 2010). Studies have shown that peanut sensitization caused by environmental 
exposure is increased in children with AD which indicates that the defective skin barrier 
caused by AD allows penetration of environmental allergens through the skin and promotes 
systemic allergen sensitization leading to the development of the so-called atopic march 
(Brough et al., 2015). Therefore, it is important to understand the underlying 
pathophysiologic and genetic mechanisms leading to the manifestation of AD. 
 
1.1.3 Pathogenesis of AD 
The etiology of AD involves a complex interplay between environmental triggers, 
susceptibility genes and altered immune responses (Elias et al., 2008). 
 
1.1.3.1 Environmental factors 
Studies have shown that microbial antigens can exacerbate AD. Comparing with 5-10% of 
healthy individuals who carry Staphylococcus aureus, 90% of AD patients are colonized with 
this microorganism (Savinko et al., 2005). There is increasing evidence show that S. aureus 
secreted superantigen can penetrate into the dermis and triggers cutaneous inflammation. 
Even low dose of superantigen secreted by S. aureus can amplify aeroallergen-induced 
responses in patch tests (Werfel, 2009). 
Clinical studies also suggest that contact with aeroallergens is important in determining 
disease expression. House dust mite (HDM) can be considered as a predominant provider of 




classified according to their sequence homology and biological function (Thomas et al., 2002). 
The degree of sensitization to aeroallergens is directly associated with the severity of AD. A 
previous study found that more than 80% of AD patients had IgE specific to HDM in their 
serum compared with 42% of asthmatic subjects (Boguniewicz and Leung, 2011). Atopic 
individuals have higher number of circulating HDM-specific T cells than non-atopic controls 
(Nurse et al., 2000).  T cells isolated from AD lesional skin and allergen patch test sites 
recognize HDM and other aeroallergens, providing evidence that inhalant allergens could 
exacerbate the inflammatory response in AD (Leung and Bieber, 2003).  
 
1.1.3.2 Multi-functional role of filaggrin 
Recent advances in the genetics and pathophysiology of AD contribute to our understanding 
of the etiology of AD. Dry skin and increased trans-epidermal water loss are hallmarks of AD, 
which indicate an impairment of skin barrier function. Decreased skin hydration alone is able 
to stimulate epidermal hyperplasia and early evidence of inflammation, such as mast cell 
degranulation, even in normal skin. There is increasing evidence showing that a combination 
of genetic and acquired factors contribute to reduced epidermal differentiation and down-
regulation of epidermal barrier function. In a search for susceptibility loci for AD, a number 
of gene variants have been linked to AD such as genes encoding a cluster of proteins in the 
epidermal differentiation complex located on chromosome 1q21 which includes filaggrin 2, 
hornerin, and the cornified envelope precursor SPRR3 (Marenholz et al., 2011). Aside from 
the epidermal differentiation complex, loss-of-function mutations in serine protease inhibitors 
such as SPINK5 have been suggested to contribute to AD by enhancing protease-activated 




cytokine, thymic stromal lymphopoietin (TSLP) (Cork et al., 2009). 
To date, the strongest evidence for a primary structural abnormality contributing to the 
pathogenesis of AD is loss of function or missense mutations in the gene FLG encoding 
filaggrin (filament-aggregating protein), a protein that is important for epidermal 
differentiation, desquamation and barrier function. Copy number variation of FLG genes 
contributes to the risk of AD as well (Palmer et al., 2006). A recent study showed that 
epigenetic modification leading to reduced expression of FLG also significantly increased the 
risk of AD (Ziyab et al., 2013). The ‗outside-inside‘ hypothesis suggests that filaggrin 
deficiency in AD contributes to a leaky skin epithelial barrier which allows enhanced 
aeroallergen and microbe penetration resulting in epicutaneous sensitization and decreased 
hydration of the stratum corneum with increased trans-epidermal water loss (Elias et al., 
2008).  
Filaggrin is a major structural component of the cornified envelope, which is synthesized as a 
large precursor, profilaggrin, stored in the keratohyalin granules in the granular layer. During 
the transit from the granular cell layer to coenocyte, filaggrin is generated by proteolysis of 
profilaggrin mediated by enzymes  such as furin, endoproteinase 1, calpain 1, matriptase, and 
elastase and released to aggregate keratin intermediate filaments into macrofibrils (Thyssen 
and Kezic, 2014). During the final cornification steps, filaggrin is proteolytically degraded 
into its constituent amino acids by caspase-14, calpain 1, and bleomycin hydrolase, which 
includes glutamine, arginine, and histidine, as well as their downstream deiminated 
metabolites. Histidine, which constitutes about 10% of the amino acids in filaggrin, is 
converted to trans-urocanic acid (trans-UCA) by histidase and glutamine, and further 
converted into pyrolidine carboxylic acid (PCA). Trans-UCA and PCA are the main 




hydration and pH (O'Regan et al., 2009) (Fig 1.2).  
Depending on the population, FLG mutations are found in 25% to 50% of patients with 
severe AD (Weidinger et al., 2006). Low filaggrin expression is also found in AD patients 
with no detectable FLG-null mutations indicating that the levels of filaggrin expression are 
also modulated by other factors than the filaggrin genotype. Indeed, multiple causes 
contribute to the low expression of FLG in skin. A variety of cytokines including IL-4 and IL-
13  have been shown to inhibit expression of filaggrin leading to the outside-inside-outside 
pathogenic loop in AD (Howell et al., 2007). Exposure to low ambient humidity and skin 
irritants enhances filaggrin proteolysis (Katagiri et al., 2003). 
 
Fig1.2 Filaggrin breakdown in the epidermis. Filaggrin is proteolytically degraded into its constituent 
amino acids by enzymes such as caspase-14. Histidine further converts to trans-UCA and PCA, which are 
the main components of the natural moisturizing factors. Trans-UCA converts to cis-UCA on exposure to 
UV irradiation.  
AD patients with filaggrin null mutations compared with patients with normal filaggrin 
expression have early onset of disease, a more persistent course and a higher risk of IgE 




which might contribute to their 7-fold increase in the risk of S aureus infections (Cai et al., 
2012). AD patients with FLG mutations have decreased expression of sphingomyelinase, 
which has been found to protect keratinocytes by reducing staphylococcal α-toxin binding 
(Brauweiler et al., 2013). Increased expression of IL-1 cytokines and stress responses 
mediated by type 1 interferon in the stratum corneum have been reported in patients with 
filaggrin null mutations (IRVINE, 2014). A positive association between FLG null mutations 
and allergen-specific CD4+Th2 response has also been reported (McPherson et al., 2010).  
Filaggrin deficiency provokes a defective antimicrobial barrier and reduces the inflammatory 
thresholds to topical irritants (Elias and Schmuth, 2009). Filaggrin-deficient mice develop 
eczema as expected after skin exposure of allergens or microbes (Oyoshi et al., 2009). 
Filaggrin deficiency has also been shown to affect keratinocyte architecture. In flaky tail mice 
which is profilaggrin deficient, the expression of E-cadherin and occludin is reduced as well 
as the expression of growth factor receptors (Nakai et al., 2012). Similar results have been 
reported in AD patients with FLG mutations (Gruber et al., 2011). The breakdown products of 
filaggrin acidify the stratum corneum (SC) and decreased filaggrin metabolites increase the 
pH of SC leading to activation of several kinds of serine proteases. Activation of proteinase-
activated receptors (PAR)-2 by endogenous and exogenous proteases delays epithelial 
regeneration and further compromises skin barrier function (Cork et al., 2009). Proteases also 
break down corneodesmosomes leading to compromised intercellular connections (Cork et al., 
2009). Recent studies have shown that AD might be prevented by early application of 
emollient to protect the skin barrier (Simpson et al., 2014). Taken together, these evidence 





1.2 Regulatory T cell differentiation and function 
DCs take up antigen and travel from the site of infection into the draining lymph nodes, 
where they activate antigen-specific T lymphocytes. The activated T lymphocytes then 
undergo proliferation and differentiation into effector cells. Different helper T cell 
populations are defined by their unique patterns of cytokine secretion (Fig 1.3). Th1 cells are 
characterized by production of IFN- γ and responsible for clearing intracellular pathogens 
whereas Th2 cells produce IL-4, IL-5, and IL-13 and are key players for clearing extracellular 
pathogens and in helping B cells to produce antibodies. Th17 cells produce IL-17 and IL-22, 
which are important in regulating antimicrobial peptides production in keratinocytes. Th22 
cells are defined by the production of IL-22, which induces epidermal hyperplasia and inhibit 
terminal differentiation. Regulatory T cells (Tregs) are important in maintaining self-tolerance 
and immune homeostasis. Therefore, their dysfunction can lead to chronic inflammation as 
seen in severe autoimmune diseases, and allergy.                   
 





1.2.1 Types of Tregs 
 Tregs are key to maintain self-tolerance and immune homeostasis. Tregs inhibit the 
activation, proliferation and effector function of several immune cells including T cells, B 
cells, NK cells and antigen presenting cells. Therefore, their dysfunction can lead to chronic 
inflammation as seen in severe autoimmune disease and allergy. Tregs can be divided into 
two major groups: the thymus-derived natural Tregs and adaptive Tregs that derived extra-
thymically. 
 
1.2.1.1 Thymus-derived natural Tregs (nTregs) 
Thymus-derived CD4+CD25+ T cells are considered to be natural Tregs (nTregs), the 
development of which involves T cell receptor (TCR) activation by self-peptide-MHC 
complexes presented by thymic stromal cells (Maloy and Powrie, 2001). They are capable of 
recognizing diverse self-antigens and prevent the activation of self-reactive T cells developing 
into effector T cells in the periphery (Bluestone and Abbas, 2003). 
 
1.2.1.2 Adaptive (Induced) Tres (iTregs) 
Adaptive Tregs develop as a consequence of activation of naive T cells under particular 
conditions of sub-optimal antigen exposure and/or co-stimulation. 
 
1.2.1.2.1 Foxp3+ iTregs 
Foxp3+Tregs can be induced from peripheral naïve CD4 T cells in several experimental 
settings. In vitro experiments have shown that stimulation of naïve T cells in the presence of 
TGF-β promotes Foxp3+Treg differentiation. IL-2 promotes differentiation of murine naïve T 
cells to Foxp3+Tregs induced by TGF-β while it inhibits their differentiation to inflammatory 




DCs in the gut-associated lymphoid tissue, facilitates the differentiation of naive T cells to 
Foxp3+ Tregs in the presence of TGF-β (Benson et al., 2007). 
 
1.2.1.2.2 Type 1 regulatory T cells (Tr1) 
Besides Foxp3+ iTregs, other types of Tregs can be induced from naïve T cells in the 
periphery. Type 1 regulatory T cells (Tr1) can be generated by stimulating naïve T cells in the 
presence of the suppressive cytokine IL-10 (Buckner and Ziegler, 2004). These Tr1 cells then 
exert their regulatory function by secreting IL-10 and TGF-β. It is reported by Kemper et al 
that human Tr1 cells can be generated by stimulating CD4+ T cells by co-ligation of CD3 and 
the complement regulator CD46 in the presence of IL-2, which exhibited strong and 
prolonged proliferation when stimulated (Kemper et al., 2003). Tr1 cells have been shown to 
control immune responses both in vitro and in vivo. Once Tr1 cells are activated through their 
TCR, their cytokine secretion means that they can exert bystander suppressive activity against 
T effector cells that recognize other antigens (Allan et al., 2008). 
 
1.2.1.2.3 T helper 3 cells (Th3) 
It has long been recognized that oral tolerance induces the generation of antigen-specific 
regulatory T cells known as Th3 cells (Weiner HL et al., 2001). Th3 cells produce TGFβ but 
no IL-10, which mediates the suppression of Th3 in in vivo transfer tolerance murine models. 
Reduced number of peripheral Tregs was found in TGFβ1 deficient mice. Mice, which 
overexpressed a dominant negative TGFβ II receptor on T cells leading to the lack of ability 
to respond to TGFβ, develop a fatal autoimmune lymphoproliferative disease, which suggests 






1.2.2 Signals which drive Tregs differentiation 
Foxp3 is a forkhead box transcription factor and the master regulator for Treg differentiation 
and function, as evidenced in scurfy mice and in patients with immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Although human CD4 effector 
T cells transiently express Foxp3 after activation, stable and high expression of Foxp3 is 
required for suppressive function of Tregs. Foxp3 transduction in CD4+CD25- T cells 
converts them to functional CD4+CD25+ Tregs, which also leads to the expression of other 
Treg associated surface molecules, such as cytotoxic T cell associated antigen-4 (CTLA-4) 
and glucocorticoid-induced TNF receptor family-related gene/protein (GITR) (Hori et al., 
2003). These results imply that high level of Foxp3 expression is able to induce suppressive 
function in T cells. Besides transcription factors, genome-wide studies have shown that nearly 
700 genes can be modulated by Foxp3 directly or indirectly including molecules involving 
signal transduction, cytokines, cell metabolism related enzymes. (Marson et al., 2007) 
Another molecule that is important for the differentiation and function of Tregs is Interleukin 
2 (IL-2). CD25, which is an important marker for Tregs, is a component of the high affinity 
IL-2 receptor (IL-2R). The crucial role of IL-2 in Treg function has been demonstrated in 
mice lacking IL-2, which spontaneously develop T cell-mediated fatal lymphoproliferative/ 
inflammatory disease and have decreased number of Foxp3+Tregs (Antony et al., 2006). 
Neutralizing IL-2 with monoclonal antibody in normal neonatal mice decreased the number 
of CD4+CD25+Foxp3+ Tregs and lead to the elicitation of autoimmune diseases (Setoguchi 
et al., 2005). In vitro experiments have shown that sustained expression of CD25 and Foxp3 
require IL-2, which also enhances the suppressive ability of Tregs (Fontenot et al., 2005). 
Therefore, a negative feedback loop exists between activated T effector cells and Tregs, that 





1.2.3 Mechanisms of Treg-mediated suppression 
Several mechanisms have been proposed to mediate suppressive function of regulatory T cells.  
 
1.2.3.1 Suppression by inhibitory cytokines 
Interleukin‑10 (IL-10) and TGFβ have been suggested as mediators of Tregs induced 
immunosuppression. For example, IL-10 produced by UV-induced Tregs mediates the anti-
tumour responses in a UV-radiation-induced murine model of carcinogenesis (Loser et al., 
2007). Neutralising IL-10 and/or TGF-β reverses the suppression of the proliferative allo-
response induced by Tr1 cells. IL-10 secreting Tr1 have also been shown to suppress antibody 
production of B cells and antigen presenting ability of monocytes and dendritic cells 
(Buckner and Ziegler, 2004). The importance of IL-10 produced by Tregs as a mechanism of 
Treg mediated suppression depends on the target and the disease model. In murine 
inflammatory bowel disease induced by Treg depletion, IL-10 produced by Tregs have been 
shown to be essential in suppression of colitis while in a murine allergy and asthma model, 
suppression of disease only partially depends on IL-10 (Vignali et al., 2008). 
TGFβ produced by Tregs has been reported to suppress inflammation by rendering responder 
T cells sensitive to suppression and/or maintaining Foxp3 expression and suppressive activity 
in Tregs (Sakaguchi et al., 2008). TGFβ has also been suggested to promote the development 
of IL-10 secreting Tregs, as neutralizing TGFβ inhibits the conversion of CD4+Foxp3- 
effector T cell to CD4+Foxp3+IL-10 secreting Tregs in intestine-associated lymphoid tissues 
(Shevach, 2009). Although some in vitro studies showed that neutralizing TGFβ did not 
reverse Treg mediated suppression, it is suggested by Nakamura et al that TGFβ produced by 
Tregs binds to the cell surface and mediates suppression in a cell contact dependent fashion. 
The regulatory activity of TGFβ is affected by several factors such as the differentiation states 




molecules and inflammatory cytokines. For example, TGFβ inhibits naïve T cell proliferation 
by suppressing the expression of IL-2 while it has minimal effect on activated T cells which 
have reduced expression of TGFβRII expression (Li et al., 2006). 
Besides IL-10 and TGFβ, IL-35 which belongs to the IL-12 heterodimeric cytokine family is 
described to be expressed by Tregs and is required for their suppressive function (Vignali et 
al., 2008). IL-35 is formed by Epstein-Barr-virus-induced gene 3 (Ebi3, which encodes IL-
27β) and interleukin-12 alpha (Il12α, which encodes IL-12α/p35). Cell contact between 
suppressor and responder cells induces Ebi3 and Il12α mRNA expression in Tregs leading to 
the maximal IL-35 production (Shevach, 2009). Recombinant IL-35 suppresses T-cell 
proliferation in vitro while Tregs from Ebi3-/- and IL-12α-/- knockout mice have decreased 
suppressive function and cannot control inflammatory bowel disease in vivo. (Collison et al., 
2007). 
 
1.2.3.2 Suppression by cytolysis 
Granzymes contain a family of serine proteases and are stored within cytoplasmic granules of 
CD8 cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Granzymes induce cell 
apoptosis by cleaving and activating intracellular caspases. Gondek C et al suggest that 
Granzyme B is one of the key mechanisms which mediate the cell contact dependent 
suppression of Tregs by showing that Tregs from GZ-B-/- mice have reduced suppressive 
ability compared to Tregs from wild type mice (Gondek et al., 2005). Adaptive Tregs, which 
are generated by stimulating CD4 T cells with CD3 and CD46 in the presence of IL-2, 
express granzyme B and kill autologous target cells in a granzyme B and perforin dependent 
manner (Grossman et al., 2004). The target cells for the granzyme B mediated cytolytic 





1.2.3.3 Suppression by targeting DCs 
Tregs are proposed to induce expression of immunosuppressive molecules in DCs. Co-
stimulatory molecule cytotoxic T‑lymphocyte antigen 4 (CTLA-4) is constitutively expressed 
by Tregs. The interaction between CTLA-4 and CD80/CD86 on DCs resulted in Indoleamine 
2, 3-dioxygenase (IDO) expression, which catalyses tryptophan metabolism and leads to the 
production of pro-apoptotic metabolites (Fallarino et al., 2003). 
Tregs are proposed to modulate the maturation and function of DCs, which in return modulate 
the activation of effector T cells. Ilona Kryczek et al reported that Tregs induced IL-10 
secretion from antigen presenting cells (APCs) and promoted the expression of B7-H4 on 
APCs via IL-10, which renders APCs immunosuppressive (Kryczek et al., 2006). Namita 
Misra et al suggested that human mo-DCs co-cultured with autologous CD4+CD25+ Tregs 
had reduced level of co-stimulatory molecules expression including CD86, CD40 and HLA-
DR and increased IL-10 secretion (Misra et al., 2004). 
 
1.2.3.4 Suppression by cell-contact dependent effect 
1.2.3.4.1 Membrane bound TGFβ 
Both in vitro and in vivo studies have proved that membrane-bound TGFβ is critical for nTreg 
function (Gandhi et al., 2010). Following a post-translational maturation, the amino terminal 
domain of TGFβ binds non-covalently with latency-associated peptide (LAP), which is a pro-
peptide, forming an inactive form of TGFβ. Nakamura et al showed that mouse CD4+LAP+ 
Tregs exerted their suppressive function via a TGFβ–dependent manner and were effective in 
suppressing autoimmunity in a murine model of multiple sclerosis (Nakamura et al., 2004). 
Several cell surface proteins have been reported to be involved in the activation of 
membrane-bound TGFβ, which includes thrombospondin-1, CD36 on macrophages and 




binding of TGFβ to a heteromeric complex, which comprises TGFβ type I (RI) and type II 
(RII) receptors. Ligand binding leads to phosphorylation of downstream signalling proteins 
including SMAD2 and SMAD3, which then translocate into the nucleus and modulate 
transcription directly or indirectly by binding with other transcription factors (Fontenot et al., 
2003). 
Chen et al showed that responder cells up-regulate the expression of TGFβ receptor type II 
after being activated through TCR, which provided the opportunity for suppressor derived 
TGFβ to bind to activated responder cells and transduce suppressive signals via contact-
dependent manner, as evidenced by the increased phosphorylation of SMAD2/3 in responder 
cells upon contact with suppressor cells (Chen and Wahl, 2003) 
 
1.2.3.4.2 CTLA-4 
Human T cells express HLA-DR and co-stimulatory molecules upon activation. Therefore, 
costimulatory pathways provide a mechanism to promote the development and function of 
Tregs in the absence of APC as well as control the fate of naive T cells upon antigen 
encounter. CTLA-4 is constitutively expressed on Tregs (Fife and Bluestone, 2008). Active 
form of membrane bound TGFβ  and TGFβ  receptor type II expression on CD4+CD25+ 
suppressor T cells were up-regulated by CTLA-4 ligation. CTLA-4-B7 interactions have also 
been shown to occur directly between Treg-Teff, which contributes to the suppression of Teff 
function (Paust and Cantor, 2005). CTLA-4 delivers a negative signal antagonizing early T 
cell activation by inhibiting IL-2 synthesis and cell cycle progression (Fife and Bluestone, 
2008).  
 
1.2.3.4.3 Programmed death-1(PD-l) 




peripheral T-cell function. Gene expression profiling of CD4 T cell co-stimulated with PD-1 
and CTLA-4 showed that PD-1 has stronger inhibitory effect than CTLA-4 on T cell 
activation (Francisco et al., 2010). PD-1 is induced in a variety of cells in the periphery upon 
activation including CD4+ and CD8+ T cells, NK T cells, B cells, monocytes, and some DC 
subsets (Francisco et al., 2010). 
 
PD-1 interacts primarily with two ligands: programmed death ligand-1 (PD-L1), which is 
expressed on leukocytes, non-hematopoietic cells and in non-lymphoid tissues and PD-L2, 
which is expressed exclusively on DCs and monocytes. Signalling through PD-1 limits T-cell 
function including cytokine production, proliferation and cytolytic function. PD-1 signalling 
also decreases T cell effector function related transcription factors including GATA-3 and T-
bet (Riella et al., 2012). The extent of PD-1 mediated inhibition is influenced by strong TCR 
stimulation. PD-1 suppresses T-cell function and survival directly by inhibiting early 
activation signals induced by CD28 or indirectly through IL-2, therefore, CD28 co-
stimulation and IL-2 can reverse PD-1 mediated suppression (Francisco et al., 2010).  
Studies have shown that PD-L1 is also involved in iTreg generation.  Francisco LM et al 
reported that co-stimulation with PD-L1 promotes the generation of Foxp3+iTregs. The 
expression of Foxp3 and suppressive function of Foxp3+ iTregs were also enhanced by PD-
L1 co-stimulation (Francisco et al., 2009). Since both nTregs and iTregs express PD-L1, they 
may further assist the generation of iTregs. PD-L1 expressed on iTregs may engage PD-1 on 






1.3 Altered T cell responses in AD 
1.3.1 Th2 cells in AD 
Infiltration of large numbers of T cells is considered to be one of the key features in the 
pathogenesis of AD. In acute lesional AD skin, there are increased levels of Th2 cells and 
associated cytokines (IL-4, IL-5 and IL-13), which are correlated with disease severity. In 
non-lesional AD skin, a selective expansion of Th2 cells in the dermal perivascular region is 
reported (Guttman-Yassky et al., 2011). IL-4 and IL-13 play a critical role in differentiation of 
allergen-specific Th2 cells and in immunoglobulin isotype switching to IgE leading to the 
initiation of allergic inflammation. The expression of adhesion molecules such as vascular 
cell adhesion molecule-1 (VCAM-1) on endothelial cells is enhanced by Th2 responses as 
well, which leads to increased inflammatory cell infiltration (Guttman-Yassky et al., 2011). 
The Th2 dominant microenvironment has profound impact on skin integrity by down-
regulating the expression of filaggrin, loricrin, and involucrin and the production of anti-
microbial peptide (AMP) which contributes to the overabundance of S. aureus (Howell et al., 
2007). IL-5 is suggested to be involved in eosinophil survival while another Th2 cytokine IL-
31 has been shown to increase pruritus (Raap et al., 2012). AD patients with filaggrin null 
mutations have increased level of circulating allergen-specific Th2 cells, which supports the 
‗outside-inside‘ hypothesis (McPherson et al., 2010).  
 
1.3.2 Th1 cells in AD 
AD is suggested to be a biphasic inflammation and the chronic phase used to be considered as 




of Th1 polarization is reported to be down-regulated in acute skin lesions in AD, which is 
detected at mRNA level by in situ hybridization (Werfel, 2009). IFNγ, a characteristic Th1 
type cytokine, upregulated Fas expression on keratinocytes which binded with Fas ligand 
expressed on activated T cells leading to keratinocyte apoptosis (Goyette and Geczy, 2011). 
Downregulation of IFNγ but not IL-4 in the skin correlates with disease improvement after 
treatment(Werfel, 2009).  
 
1.3.3 Th17 cells in AD 
A few studies have investigated the role of IL-17-secreting Th17 cells in the pathogenesis of 
AD. Immunohistochemistry studies have showed that Th17 axis is preferentially increased in 
acute AD skin lesions and circulation while it is reduced in chronic lesions (Koga et al., 2008).  
In acute lesions, increased production of IL-17 is induced by Staphylococcal enterotoxin B, 
which may directly contribute to the acute phase of AD by inducing B cells to produce 
antigen-specific IgE (Toda et al., 2003; Milovanovic et al., 2010). It has been shown in a 
murine model that filaggrin deficiency predisposes Th17-dominated skin inflammation, the 
severity of which is positively correlated with IL-17 expression in epidermis (Oyoshi et al., 
2009).  IL-17 has been shown to induce AMP production in human keratinocytes both in vitro 
and in vivo although this effect is inhibited by Th2 cytokines leading to increased 
susceptibility to bacterial infection in AD (Novak and Leung, 2011).  
 
1.3.4 Th22 cells in AD 




(Tc22) cells has been found to be increased in AD, the frequency of which is associated with 
AD severity (Eyerich et al., 2009). IL-22 affects keratinocyte function by inhibiting terminal 
differentiation and increasing proliferation leading to epidermal hyperplasia (Nograles et al., 
2009). Enhanced epicutaneous antigen penetration induced by defective barrier in AD is 
process by LCs in epidermis, which will activate Th2 and Th22 immune responses and 
promote the aggravation of AD (Fujita et al., 2009). IL-22 production can also be induced by 
staphylococcal enterotoxin B (Niebuhr et al., 2010). IL-22 has been reported to affect the 
expression of pro-filaggrin processing enzyme leading to downregulation of filaggrin, thus 
further disrupting epidermal barrier function in AD (Gutowska‐Owsiak et al., 2011). 
 
1.3.5. Tregs in patients with AD 
Tregs play a vital role in the resolution of allergic immunity and increasing their number 
and/or function may offer benefit to AD patients. Controversial results have been published 
about the number and function of Treg cells in AD patients. , as further described below. Not 
all the studies actually identified Tregs in the same way and this might lead to some of the 









Table 1.1 Summary of phenotypes used to define Tregs in human. 
Phenotype of human Tregs Reference  
CD4+CD25+ Tregs (Dieckmann et al., 2001) 
CD4+CD25hi Tregs (Baecher-Allan et al., 2005) 
CD4+CD25+Foxp3+ Tregs (Walker et al., 2003) 
CD4+CD25hiFoxp3+ Tregs (Ahmadzadeh and Rosenberg, 2006) 
CD4+CD25+Foxp3+CD127lo/- Tregs (Liu et al., 2006) 
CD4+CD25+ CD127lo/- Tregs (Hartigan-O'Connor et al., 2007) 
 
1.3.5.1 Studies reporting decreased number and function of Tregs in patients with AD 
Some studies demonstrate decreased frequency and function of Tregs in AD patients. 
Stelmaszczyk-Emmel et al investigated the role of CD4+CD25 (+/high) FoxP3+ CD127- 
Tregs  in 20 allergic patients among whom 10 had AD. Compared with healthy controls, a 
significantly decreased frequency of Tregs was observed in all patients, which negatively 
correlated with concentration of allergen-specific IgE (Stelmaszczyk-Emmel et al., 2013). 
This observation was confirmed by Ma et al who showed that the percentage of CD4+ 
CD25high Foxp3+ Treg was decreased in peripheral blood and in cell suspensions obtained 
from skin samples obtained from patients with AD. Besides CD4+ CD25high Foxp3+ Tregs, 
serum concentration of the immune suppressive cytokine TGFβ was decreased as well as its 




Immunohistochemistry showed absence of CD25+Foxp3+ Treg in skin lesions from AD 
patients (Verhagen et al., 2006). Defective regulatory activity of CD25+ Tregs has been 
reported in two studies and their deficiency were associated with the atopic status of AD 
patients (Zhang et al., 2015; Ling et al., 2004). 
 
1.3.5.2 Studies reporting similar number and function of Tregs in patients with AD 
On the other hand, several studies report that AD patients have similar number of Tregs as 
healthy individuals. Vukmanovic‐Stejic, et al reported that there was no difference in 
frequency of CD4+CD25+ T cells in peripheral blood of AD patients compared with healthy 
controls. CD4+CD25+ T cells isolated from AD patients inhibited proliferation of 
CD4+CD25- cells induced by purified protein derivative or Derp1 to a similar extend as those 
from healthy controls (Vukmanovic ‐ Stejic et al., 2005).  It has been shown that 
CD4+CD25+ T cells from the majority of AD patients who are allergic to grass or birch 
pollen exhibit normal suppressive function by inhibiting proliferation and cytokine 
production of Th1 and Th2 cells. No difference in the frequency of CD4+CD25+ T cells was 
observed in these patients as well (Bellinghausen et al., 2003). 
 
1.3.5.3 Studies reporting increased number and function of Tregs in patients with AD 
Moreover, there are also studies suggesting that the frequency of Tregs is increased in AD. 
Several studies have shown that patients with AD have increased numbers of Foxp3+Tregs in 
peripheral blood compared to healthy control, and this is positively correlated with their AD 




et al., 2012). Treatments that improve skin lesions such as cyclosporin A significantly 
decrease Foxp3+Tregs frequency in peripheral blood and expression of Foxp3 in CD4 T cells 
at mRNA level (Hijnen et al., 2009).  
Fujimura et al also reported that the epidermis and dermis of AD skin contain substantial 
number of CD25+Foxp3+ Tregs while in normal skin Foxp3+Tregs are rare (Fujimura et al., 
2008). This observation is confirmed by Caproni M et al who showed that increased numbers 
of CD25+ Foxp3+ cells are distributed in the perivascular, interstitial, and periadnexal dermis 
compared with healthy skin (Caproni et al., 2007). 
Although the studies mentioned above report increased frequency of Foxp3+Tregs, 
controversial results about function of Foxp3+Tregs in these studies have been shown. 
Samochocki et al suggest that CD4+CD25hi Foxp3+ cells from severe AD patients may have 
enhanced suppressive function as evidenced by increased expression of CD62L and CD134 
and decreased expression of apoptotic CD95 receptor (Samochocki et al., 2012). Ou et al 
investigate function of CD4+CD25+ from patients with AD and non-atopic healthy control 
subjects by co-culturing them with autologous CD4+CD25- effector cells stimulated by anti-
CD3 or staphylococcal enterotoxin B.  They demonstrate that proliferation of effector cells is 
equally suppressed by CD4+CD25+ cells from patients with AD or controls when effector 
cells are activated by anti-CD3 while the suppressive function of CD4+CD25+ cells is lost 
when effector cells are stimulated by staphylococcal enterotoxin B (Ou et al., 2004). It is also 
suggested that skin-homing CD4+Foxp3+ Tregs are heterogeneous, which could be further 
divided into two subtypes based on expression of the chemokine receptor CCR6. CCR6- cells 
within skin-homing CD4+Foxp3+ Tregs produce the Th2 cytokine IL-5 after Staphylococcal 
enterotoxin B stimulation while the CCR6+ subtype produces the anti-inflammatory cytokine 




Tregs may be differentially affected and it is important to test the function of cells with Tregs 
phenotype. 
The presence of IL-10 secreting Type 1 regulatory T cells (Tr1) have been investigated as 
well. A Szegedi et al show that the number of Tr1 is significantly increased in peripheral 
blood of AD patients (Szegedi et al., 2009).  The presence of Tr1 in AD skin has been 
confirmed by Verhagen et al who also show that Tr1 related cytokines including IL-10 and 
TGFβ and their receptors are abundantly expressed in AD skin (Verhagen et al., 2006). Taken 
together, these data suggest that one of the reasons contributing to controversial results of 
Tregs in AD patients may be that different markers are used to identify Tregs in humans.  
 
1.4 Narrowband UVB Phototherapy 
The UV wavelengths are divided further into three ranges as shown in Fig 1.4: UVA (320-400 
nm), UVB (290-320 nm), and UVC (100-290 nm). The UVA spectrum has been subsequently 
divided up into UVA-1 (340-400 nm) and UVA-2 (320-340 nm). Within solar irradiation, 
UVC radiation and majority of UVB radiation are blocked by the ozone layer in the 
stratosphere and does not reach the earth‘s surface. Phototherapy uses a specific wavelength 
of UV radiation relying on controlled artificial light sources to treat a variety of skin diseases. 
The symptoms of the majority of AD patients improve with first-line topical treatment 
including emollients, corticosteroids and calcineurin inhibitors and environmental trigger 
avoidance. Phototherapy is recommended in both acute and chronic AD after failure of first-
line treatment. Phototherapy can also be used as maintenance therapy and is indicated for 
patients with chronic disease. Narrowband UVB (NB-UVB) therapy uses a fluorescent bulbs 
emitting a major peak at 311 (±2 nm) and a minor peak at 305 nm. Compared with other 




considering its low risk profile, relative efficacy and availability (Eichenfield et al., 2014) 
 
 
Fig 1.4 Spectrum of Sunlight and damage caused by different UV wavelength. 
 
1.4.1 Mechanisms of NB-UVB phototherapy in treating AD 
The goals of phototherapy are to suppress on-going inflammatory processes and to prevent or 
modulate the pathogenic mechanisms causing the disease. NB-UVB phototherapy has proved 
effective in treating AD and other inflammatory skin diseases, however, detailed 
understanding of the mechanisms underlying phototherapy remain elusive.  As the biological 
effects of UVB are the best understood, the mechanisms summarised below will focus on the 




1.4.1.1 UV-induced apoptosis 
Considering the important role of T cells in the pathogenesis of AD, the therapeutic effect of 
UVB is mediated partially by depleting effector T cells in skin.  In vitro experiments have 
shown direct toxic effect of UVB on pure T cell populations. Besides direct toxicity, 
induction of apoptosis by UVB is the primary mechanism of depleting skin-infiltrating T cells 
(Weichenthal and Schwarz, 2005). Studies have shown that NB-UVB phototherapy is 
superior compared to broadband UVB phototherapy in depleting T cells from skin lesions. 
(Novák et al., 2002). It has been reported that several pathways, which act in an additive 
manner, are involved in UVB induced apoptosis including UVB-induced DNA damage 
(cyclobutane pyrimidine dimers and (6–4) photoproducts) and direct activation of death 
receptors ligand such as CD95Lon keratinocytes leading to neighbouring lesional T cell 
apoptosis (Weichenthal and Schwarz, 2005). 
 
1.4.1.2 UV-induced immunosuppression 
There is increasing evidence showing that UVB therapy induces both local and systemic 
immunosuppressive effects which may contribute to the clinical efficacy of NB-UVB 
phototherapy (Schwarz, 2008). UVB has been suggested to modulate LCs to induced local 
immunosuppressive effects. Low dose UVB has been shown to promote the emigration of 
LCs to cutaneous lymph nodes while high dose UVB induced apoptosis of LC, both of which 
lead to decreased number of LCs in the epidermis. Besides, antigen presenting ability of LCs 
is also inhibited by UVR, which has been proven both in vitro and in vivo. UVB induced 
down-regulation of CD80/CD86 expression on LCs and blood derived DCs which contribute 




UVB-damaged DNA release IL-10, which affects antigen presentation by LCs and 
contributes to the systemic immunosuppression of UVB (Nishigori et al., 1996). Neutralizing 
IL-10 reverses UVR induced systemic immunosuppression of induction of delayed type 
hypersensitivity.  
 
1.4.1.3 UV-induced Tregs 
One of the major hallmarks of UVB-induced immunosuppression is that it acts in an antigen-
specific fashion, thus differing from the more general immunosuppression induced by 
immunosuppressive drugs. UVB-induced, antigen specific, Tregs have been characterized in 
several murine model and Tregs with unique phenotypes are involved. The best characterized 
UV-induced Tregs are those in the experimental murine model of contact hypersensitivity. 
They express CD4, CD25, CTLA-4, dectin-2, glucocorticoid-induced TNF receptor family–
related protein (GITR), neuropilin, and CD62L but not the ligands for the skin-homing 
receptors E- and P-selectin. A small subtype of UV-induced Tregs expresses the transcription 
factor FoxP3 (Schwarz, 2005b). Tregs have to be activated in an antigen-specific manner to 
exert their suppressive function. In vitro activation with the specific antigen induced the 
release of IL-10 by UV-induced Tregs. One of the mechanisms by which UV irradiation 
induces Tregs is through LCs. UVB damaged but viable LCs is required in regional lymph 
nodes for the generation of Tregs (Schwarz et al., 2010). Besides this mechanism, receptor 
activator of NF- κB (RANK) and its ligand RANKL are also involved in the induction of UV-
induced Tregs. Enhanced number of CD4+CD25+ cells are observed in mice that overexpress 
RANKL in basal keratinocytes. RANKL expression on keratinocytes induced by UVB 




antimicrobial peptide β-defensin-14 induced by UV irradiation converts CD4+CD25- effector 
T cells into functional Foxp3+Tregs leading to inhibition of sensitization upon adoptive 
transfer into naïve mice in contact hypersensitivity model (Navid et al., 2012). Taken together, 
these results suggest that multiple pathways are involved in UV-induced Tregs generation.  
 
1.4.1.4 UV-induced anti-inflammatory molecules 
It is well known that UV radiation induces the production of vitamin D, which is considered 
as an important immune regulatory molecule. Topical vitamin D analogs have been 
successfully used in treating psoriasis. Therefore, it is suggested that UV-induced vitamin D 
is responsible for the clinical beneficial effect of UVB phototherapy. However, UV radiation 
could suppress immune responses independently of vitamin D (Schwarz et al., 2012), as 
further discussed below.  
 
1.4.1.4.1 UV-induced vitamin D 
UVB photolyses 7- dehydrocholesterol to cholecalciferol in the skin, which is then 
hydroxylated in the liver and kidney to form the most active form of vitamin D 1,25(OH)2D3 
(Lehmann et al., 2001)  
1,25(OH)2D3 (vitD) is an important mediator induced by UVB therapy with immune 
regulatory functions which play an important role in preventing progression of AD. VitD 
impairs the differentiation of monocytes into DCs and decreases the expression of co-
stimulatory molecules and secretion of cytokines from cultured monocytes and DCs (Baeke et 




IL-10-secreting Tregs, respectively (van der Aar et al., 2011). In addition, vitD has direct 
effects on CD4+ T cells by inducing the development of Foxp3+Treg and enhancing the 
secretion of IL-10 (Etten and Mathieu 2005). VitD also has a direct effect on B cells by 
reducing their differentiation into memory and plasma B cell subtypes and their capacity to 
produce antibody (Etten and Mathieu, 2005). 
 
1.4.1.4.2 UV-induced nitric oxide (NO) generation 
The nitrate–nitrite–NO pathway in normal physiology and in pathological hypoxia 
complements the classical L-arginine-NOS pathway, which is largely dependent on oxygen to 
ensure NO production in situations for which the oxygen-dependent NOS enzyme activities 
are compromised. 
 
1.4.1.4.2.1 Sources for NOS-independent NO generation 
Nitrate, nitrite and RXNO (the sum of S-nitrosothiols (RSNOs), N-nitrosamines (RNNOs), 
iron-nitrosyl species) form the major nitro-species present in skin and in circulation and serve 
as a stable endocrine carrier of NO (Kelm, 2005). Endogenous NO, generated by NOS 
enzymes, is oxidized in the blood and tissues to form nitrite, a process catalysed by the multi-
copper oxidase and NO oxidase ceruloplasmin in plasma (Shiva et al., 2006). It has been 
shown that nitrite has short half-life in whole blood (±110 seconds) and rapidly oxidizes to 
nitrate in the range of minutes. Nitrate in human plasma compared to nitrite has a longer half-
life of approximately 8 hours, and this forms the largest store of nitro-species (Moshage et al., 
1995). Dietary intake is one of the major sources of nitrate in the body (Lundberg and 
Weitzberg 2005). Besides this, endogenous NO can also form nitrate by reacting with 




formed by S-nitrosation of thiols and RNNOs are formed due to the reaction of nitrite with 
amino groups of food constituents in the acidic environment of stomach. 
 
1.4.1.4.2.2 Mechanisms for NOS-independent NO generation 
Commensal bacteria convert nitrate to nitrite via one–electron reduction in humans since 
mammals do not synthesize nitrate reductase. Commensal bacteria involved in this process 
include:-  bacteria in the oral cavity among which Veillonella species (V.atypica and V.dispar) 
are the most prevalent nitrate reducers (Doel et al., 2005);  bacteria on body surfaces such as 
S.aureus, S.epidermidis, and Nitrosomonas species (Weller et al., 1996);  and,  bacteria in the 
gastrointestinal tract such as Lactobacillus species (L.rhamnosus, L.acidophilus) and 
Bifidobacterium species ( B.longum infantis ) (Tiso and Schechter, 2015). 
 
In the acidic condition of the stomach, nitrite was found to rapidly generate nitrous acid 
(HNO2), which further decomposes to form NO (Benjamin et al., 1994). Reducing 
compounds such as vitamin C and polyphenols, both of which are abundant in the diet are 
suggested to enhance the process of reduction of nitrite to NO. 
 
Nitrate and nitrite recycle in blood and tissue and act as NO-storage to generate NO and other 
bioactive nitrogen oxides when oxygen tensions falls. It was reported by Doyle et al in 1981 
that nitrite reacts with deoxyhemoglobin to generate NO in regions of low oxygen tension 
where deoxyhemoglobin predominates (Doyle et al., 1981). The expression of xanthine 
oxidoreductase, the structure of which is related to bacterial nitrate and nitrite reductases, is 
greatly enhanced at low oxygen tensions and acidic conditions. It has been shown that 
xanthine oxidoreductase catalyses the reduction of nitrite or nitrate to NO (Lundberg and 




Adnana N. Paunel et al showed that upon exposure to UVA, nitrite and RSNO contained in 
human skin undergo photolysis to generate NO, the concentration of which is comparable or 
even higher than that produced by cytokine-activated human keratinocyte cultures with 
maximal iNOS activity in vitro (Paunel et al., 2005). This process is enhanced by thiols in 
vivo as shown by Dejam and colleagues who reported that upon UV irradiation, thiols (which 
are a major component of cysteine and glutathione in keratinocytes) enhance the non-
enzymatic conversion of nitrate to nitric oxide and nitric oxide-adducts (Dejam et al., 2003). 
 
1.4.1.4.3 UV induced cis-urocanic acid (cis-UCA) generation 
Urocanic acid (UCA), located in the stratum corneum, is a major epidermal chromophore and 
suggested to play a role in UV-induced immunosuppression. UCA is a histidine-derived 
molecule produced by histidase, which is converted from trans-UCA to cis-UCA after UV 
radiation. Urocanase, which catabolizes UCA to imidazolonepropionic acid and subsequently 
to glutamic acid, exists in liver but is absent in skin leading to accumulation of trans-UCA 
which takes up to 0.5% of the dry weight of the epidermis. It is suggested that the epidermal 
concentration of UCA varies from 4 to 34nM/cm
2
, and this does not correlate with age, 
gender, pigmentation, skin phototype, or minimal erythema dose (Gibbs et al., 2008). Recent 
studies suggest that the level of urocanic acid in stratum corneum is associated with FLG 
genotype and severity of AD (Kezic et al., 2011).  
 
Photoconversion of trans to cis-UCA is mainly induced by wavelengths between 310 and 340 
nm (Berneburg et al., 2005). Photoprotection provided by the conversion of trans-cis UCA is 
equal to a sunscreen with a sun protection factor (SPF) of 1.5. The major source of histidine 
in the skin is filaggrin (Denecker et al., 2007). Therefore, FLG mutation results in a lower 




radiation induced deleterious effect by 33% (Gibbs and Norval, 2011). 
 
Taken together, these evidence suggest that NB-UVB releases other potential anti-
inflammatory molecules than vitD. I further investigated the function of NO and cis-UCA on 

























NO and cis-UCA contribute to the clinical efficacy of NB-UVB phototherapy in AD through 
their effects on the function of regulatory T cells either directly, or indirectly through its 




 Study the effects of NO on the phenotype and function of human CD4+ T cells and 
mo-DCs from healthy volunteers. 
 
 Study the effects of cis-UCA on the phenotype and function of human CD4+ T cells 
and mo-DCs from healthy volunteers. 
 
 Study whether the clinical efficacy of NB-UVB phototherapy in AD is linked to 
changes in the phenotype of T cells and Tregs  
 
 Study the correlation between vitamin D/Nitrate/FLG genotype, circulating Tregs and 

















2.1.1.1 PRMI tissue culture medium 
Complete RPMI 1640 containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
μg/mL streptomycin and 2 mM L-glutamine (all Gibco, Life Technologies, Paisley, UK). 
 
2.1.1.2 DC culture medium 
RPMI 1640 buffered with 20mM HEPES (Sigma, Poole, UK), 5% AB serum (Sigma), 2 mM 
L-glutamine (Gibco), 50ng/ml GM-CSF, 15ng/ml IL-4 (both Miltenyi, Surrey, UK) 
 





 supplemented with 2% heat-inactivated FBS (both Gibco) and 
0.05% sodium azide (Sigma) 
 





supplemented with 2% heat-inactivated FBS and 1mM EDTA 
(All Gibco) 
 





supplemented with 0.5% human AB serum and 2nM EDTA  
 
2.1.1.6 Protein lysis buffer 




NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS supplemented with protease inhibitor 
cocktail (Thermo Scientific, Loughborough, UK) and 0.5% Na3PO4. 
 
2.1.1.7 Western blot sample buffer 
3X Sample buffer contains 0.19 M Tris pH 6.8, 6% SDS, 30% glycerol, 0.3M DTT, 0.02% 
bromophenol blue and dilutes with samples to 1X when needed. 
 
2.1.1.8 Western blot running buffer 
10X Running buffer contains 1.92M Glycin, 0.25M Tris base, 10% (v/v) SDS. 
 
2.1.1.9 Western blot transfer buffer 
Transfer buffer contains 25mM Tris base, 192mM glycine and 20% (v/v) methanol. 
 
2.1.1.10 Western blot washing buffer 
10X TBST Wash Buffer stock was prepared (0.1M Tris HCl, 1.5M NaCl, 0.5% Tween-20). It 
was diluted to 1X TBST with Milli Q water and used as western blot washing buffer. 
 
2.1.1.11 Western blot blocking buffer 
5% w/v non-fat dry milk dissolved in 1X TBST.  
 
2.1.1.12 Western blot stripping buffer 
Stripping buffer contains 2%SDS, 62.5 µM Tris HCL pH6.8 and 0.8% ß-mercaptoethanol 
 
2.1.1.13 Antibodies 




except where stated). For clones see Antibody Table 2.1. 
 
Surface staining: Viability dye eFluor® 780 (ebioscience), anti-CD3 AF700, anti-CD4 FITC 
(BD Pharmingen), anti-CD4 PerCP, anti-CD25 AF488, anti-CD25 APC (BD Pharmingen), 
anti-CLA Pacific Blue, anti-CD127 PE (ebioscience), anti-CD8 PE, anti-CD69 PE, anti-CD46 
FITC, anti-PD-1 PerCP, anti-PD-L1 PE-Cy7, anti-CD14 Pacific Blue, anti-HLA-DR PE-Cy5, 
anti-CD11c APC, anti-CD86 AF488, anti-CD86 APC, anti-CD80 AF700, anti-CD83 APC, 
anti-CD40 PE-Cy7,  
Intracellular staining: anti-Foxp3 PE (BD Pharmingen), anti-Foxp3 AF647 
 
Table 2.1 Flow cytometry antibody clones and dilutions 
 
Antibody Conjugate Clone Dilution 
CD3 AF700 UCHT1 1:100 
CD4 FITC/PerCP RPA-T4 1:100 
CD25 AF488 BC96 1:200 
 APC M-A251 1:100 
CLA Pacific Blue HECA-452 1:200 
CD127 PE eBioRDR5 1:25 
CD8 PE SK1 1:100 
CD69 PE FN50 1:100 
CD46  FITC MEM-258 1:200 
PD-1  PerCP EH12.2H7 1:100 
PD-L1 PE-Cy7 29E.2A3   1:100 
CD14 Pacific blue HCD14 1:100 
HLA-DR  PE-Cy5 L243 1:100 
CD11c APC Bu15 1:100 




CD80  AF700 L307.4 1:100 
CD83 AF488 HB15e 1:100 
Foxp3 PE 259D/C7 1:100 
 AF647 206D 1:50 
 
2.1.2 Chemical preparation 
All these chemicals were purchased from Sigma except where stated and were diluted to the 
required concentration using cell culture medium in each experiment. 
 
2.1.2.1 Cis-UCA preparation 
Cis-UCA stock was prepared by reconstitution at the concentration of 10 μg/μl using 
complete RPMI 1640. 
 
2.1.2.2 Trans-UCA preparation 
Trans-UCA stock was prepared by reconstitution at the concentration of 1 μg/μl using 
complete RPMI 1640. 
 
2.1.2.3 Vitamin D (vitD) preparation  
vitD stock was prepared by reconstitution at the concentration of 10
-4
M using 95% sterilized 
ethanol. 
 
2.1.2.4 Diethylenetriamine/nitric oxide adduct (DETA-NO) preparation 
NO-donating compound DETA-NO was prepared by reconstitution at the concentration of 





2.1.2.5 NOC-18 preparation  
Stable NO-donating compound 3,3-Bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene (NOC-18) 
was prepared by reconstitution at the concentration of 10mM in complete RPMI. 
 
2.1.2.6 Ketanserin (+)-tartrate salt preparation  
Ketanserin (+)-tartrate salt (Ke) was prepared by reconstitution at the concentration of 10mM 
in DMSO. 
 
2.1.2.7 α-Methylserotonin maleate salt preparation  
α-Methylserotonin maleate salt (α-Me) was prepared by reconstituted at the concentration of 
10mM in complete RPMI. 
 
2.1.2.8 LPS preparation  
LPS stock was prepared by reconstitution at the concentration of 10 mg/ml in PBS. 
 
2.2 Cell isolation and purifications 
2.2.1 Plasma isolation 
Periphery blood was collected from informed consented volunteers using 3.8% sodium citrate 
as anticoagulant. Plasma was isolated from undiluted blood by centrifuging at 445g for 10 
min at 4 °C. Following centrifugation, the resulting supernatant was aliquoted into 0.5 ml 
aliquots and stored at -80°C. 
 
2.2.2 PBMC isolation from peripheral blood 
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Hypaque PLUS (GE 




Approximately 40ml blood was collected into a 50 ml falcon tube with 4ml of 3.8% sodium 
citrate. Blood was diluted 1:1 with PBS in a 75 cm
2 
culture flask. 27 ml of diluted blood was 
layered onto 13ml Ficoll in 50ml falcon tube and centrifuged at 650g for 25 min without  
break. The PBMCs interphase was aspirated into a fresh 50 ml falcon tube and washed with 
PBMC wash buffer once by centrifuging at 300g for 10min. Then the cell pellet was washed 
another 3 times at 200g for 10 min. 
 
2.2.3 CD14+ monocytes purification 
CD14+ monocytes were isolated by positive selection with Human CD14 selection kit from 
STEMCELL (Manchester, UK) according to the manufacturer‘s instructions. PBMC were 
resuspended at a concentration of 1*10
8
 cells/mL in MACS buffer and incubated with 
EasySep positive selection antibody cocktail at 100 μL/mL cells for 15 minutes at room 
temperature. CD14+ monocytes were targeted with tetrameric antibody complexes 
recognizing CD14 and magnetic particles. Cells were then incubated with EasySep Magnetic 
Nanoparticles at 50 μL/mL for 10 minutes before brought up to 2.5mL by adding MACS 
buffer and incubated in Purple EasySep Magnet for 5 minutes. The unwanted CD14- cell 
populated were poured off by inverting the magnet and tube and the magnetically labelled 
cells were remained inside the tube holding by the magnetic field of the Purple EasySep 
Magnet. An aliquot of the cells were stained with a Pacific Blue-conjugated CD14 antibody to 
assess cell purity by FACS analysis. Purity of the monocytes was consistently >95%. 
 
2.2.4 CD4+ T cell purifications 
CD4+ T cells were isolated by negative selection with Human CD4 T cell enrichment kit 
from STEMCELL (Manchester, UK) according to manufacturer‘s instructions. CD14- cells 
after monocytes isolation were re-suspended at 5*10
7




incubated with  EasySep Human CD4+T Cell Enrichment Cocktail at 50 µL/mL cell for 10 
minutes at room temperature. Unwanted cells were targeted for removal with tetrameric 
antibody complexes recognizing CD8, CD14 ect. Cells were then incubated with EasySep™ 
D Magnetic Particles at 100 µL/mL cells for 5 minutes before brought up to 2.5mL by adding 
MACS buffer and incubated in Purple EasySep Magnet for 5 minutes. The un-touched CD4+ 
T cells were poured off by inverting the magnet. An aliquot of the cells were stained with a 
FITC-conjugated CD4 antibody to assess cell purity by FACS analysis. Purity of the CD4+ T 
cells was consistently >95%. 
 
2.2.5 Positive selection of CD4+CD25+ T cells 
CD4+CD25+ T cells were isolated by positive selection with EasySep Human 
CD4+CD25high T Cell Isolation Kit from STEMCELL (Manchester, UK) according to 
manufacturer‘s instructions. The selected CD4+ T cells (see section 2.2.4) were incubated 
with Easysep blocking buffer at 50 μl/ml for 15 minutes at room temperature. After washing 
twice with MACS buffer, cells were incubated with EasySep CD25 Positive Selection 
Cocktail at 25 μl/ml for 15 minutes and then incubated with EasySep Magnetic Nanoparticles 
at 12.5 μl/ml for 10 minutes. Magnetically labelled CD4+CD25+ T cells were then isolated 
using Purple EasySep Magnet. 
 
2.2.6 Negative selection of CD4+CD25- T cells 
CD4+CD25- T cells were isolated by negative selection with EasySep Human 
CD4+CD25high T Cell Isolation Kit from STEMCELL (Manchester, UK) according to 
manufacturer‘s instructions. The selected CD4+ T cells (see section 2.2.4) were incubated 
with Easysep blocking buffer at 50 μl/ml for 15 minutes at room temperature. After washing 




EasySep CD25 Positive Selection Cocktail at 100 μl/ml for 15 minutes to and then incubated 
with EasySep Magnetic Nanoparticles at 100 μl/ml for 15 minutes. Magnetically labelled 
CD4+CD25+ T cells were isolated using Purple EasySep Magnet. The CD4+CD25- cells 
were poured off by inverting the magnet and tube and the magnetically labelled unwanted 
CD25+ cells remained inside the tube held by the magnetic field of the Purple EasySep 
Magnet.  
 
2.3 Methods  
2.3.1 In vitro cell culture 
2.3.1.1 Mo-DCs differentiation and maturation 
CD14+ monocytes were seeded in 24-well NUNC plates (Fisher Scientific, Loughborough, 
UK) at 2* 10
6
 cells per ml per cm2 in DC culture medium with or without different treatment. 
Cells were cultured at 37°C in a humidified atmosphere of 5% CO2. One third medium with 
or without treatment was added on day 3 and day 5. On day 7, cell suspension was collected 
by centrifuging at 300g for 10 min without brake at room temperature. A fraction of the cells 
were removed for cell count and immature DC phenotype analysis. The spare cells were re-
plated at 0.5*10
6
 cells/ml in DC culture medium with addition of 20µg/ml Polyinosinic-
polycytidylic (Poly I/C) for 48h or addition of 10 ng/ml LPS for 24 hours. Cells were 
collected for mature DC phenotype analysis and supernatants were used for ELISA. 
 
2.3.1.2 CD4+ T cell activation 
48-well plates were pre-coated with anti-human CD3 (OKT3, ebioscience) and anti-human 
CD28 (CD28.2, ebioscience) at the concentration of 1 to 5 μg/ml for 2 hours at 37°C. CD4+ T 
cells were then seeded at 0.5*10
6
 cell/ml in complete RPMI1640 with or without different 




collected after 5 days for phenotype analysis and supernatants were used for ELISA. 
 
2.3.2 FACS analysis 
2.3.2.1 Surface staining 
For surface staining, cells were centrifuged at 445g for 5 minutes and then resuspended in 
FACS buffer in 96-well round bottom plate. The cell pellet was washed twice with PBS 
before incubating with 50 µl of diluted Viability dye eFluor® 780 for 20 minutes at 4°C 
protected from light. After 2 washes with FACS washing buffer, 50 µl FACS wash containing 
2% mouse serum was added and the tube was incubated on ice for 10 mins to block Fc 
receptor binding. Cells were then incubated with 50 µl surface staining antibody cocktail and 
incubated at 4°C protected from light for 20mins. Cells were washed with FACS buffer once 
and re-suspended in 300 µl FACS washing buffer. Cells were ready to be analysed on FACS 
Calibur (Becton Dickinson) or Fortessa (BD) flow cytometers. 
 
2.3.2.2 Intracellular staining 
For intracellular staining, Foxp3 was stained using Foxp3 staining buffer set from BD 
following the manufacturer‘s instructions. Cells were surface stained as described above then 
incubated in fixation buffer for 10 minutes. Cells were washed with FACS buffer then 
incubated with the permeabilisation buffer at room temperature for 30 minutes. Cells were 
washed with FACS buffer twice before stained with anti-Foxp3 PE/AF488 (BD/Biolegend) 
for 30 minutes at room temperature. Cells were washed in FACS buffer then re-suspended in 
300μl FACS buffer for collection at a rate of ~500 events/second. 
 
2.3.2.3 Whole blood staining 




FACS buffer. 50μL of cell suspension were added to a round bottom 96-well plate and stained 
with surface staining or intracellular staining as described in 2.3.2.1 and 2.3.2.2. Cells were 
then incubated with 200 μL of FACS-Lysing solution for 8 minutes at room temperature 
protected from light. The lysing process was repeated till wells appear free of haemoglobin. 
Cells were re-suspended in 200 μL FACS buffer and analysed using the Fortessa (BD) flow 
cytometer. 
 
2.3.2.4 Proliferation assay 
CD4+ T cells were stained with the proliferation dye ef670 (ebioscience) following the 
manufacturer‘s instructions. In brief, cells were incubated with diluted proliferation dye ef670 
for 10 minutes at 37°C in the dark in PBS. Cells were then incubated on ice for 5 minutes 
with complete RPMI medium to quench the reaction before being washed three times with 
complete RPMI 1640 tissue culture medium. Cells were then re-suspended complete in RPMI 
1640 culture medium at desired concentration and cultured for 4 days . 
 
2.3.2.5 Suppression assay 
Regulatory T cell suppressive function assays were set up in 96-well U-bottom plates. In brief, 
total CD4+ T cells stained with the proliferation dye ef670 as described in 2.3.2.4 (5*10
4
 
cells/well used as responders) were co-cultured with different numbers of freshly purified 
CD4+CD25+ T cells as suppressor cells in the presence of pre-coated anti-CD3/CD28 
(5μg/ml) in 200 μl of RPMI1640 tissue culture medium. The proliferation of the responder 
cells were analyzed using using the Fortessa (BD) flow cytometer.  
 
2.3.2.6 Transwell assay 




proliferation dye ef670 as described in 2.5.1.4 (10x 10
5
 cells/well used as responders) were 
cultured in the presence of pre-coated anti-CD3/CD28 (5μg/ml) in 800 μl of RPMI1640 tissue 
culture medium. Different numbers of NO-treated CD4+ T cells as suppressor cells were 
seeded in the transwell insert which separates suppressor cells from responder cells. The 
proliferation of responder cells were analyzed using using the Fortessa (BD) flow cytometer.  
 
2.3.3 Cytokine array 
The cytokine profile secreted by CD4+ T cells was analysed using the Proteome Profiler 
Human Cytokine Array Panel A kit (R&D Systems) according to the manufacturer's protocol. 
Cell culture supernatants of activated CD4+ T cells having the same treatment (cis-UCA or 
vitD or NO) from 9 healthy donors were combined together and used as samples to avoid 
variability of individual donors. Pre-coated membrane was blocked with 2ml Array buffer 4 
for an hour. 15 µL of reconstituted human cytokine array panel A detection antibody cocktail 
was mixed with 1.5ml samples and incubated for an hour before the antibody/sample 
mixtures being incubated with pre-coated membrane overnight at 4 degree. After being 
washed with wash buffer for 3 times, pre-coated membrane was incubated with 2ml diluted 
Streptavidin-HRP for 30min. After being washed 3 times, pre-coated membrane was 
incubated with 1 mL of the prepared Chemi Reagent Mix and exposed to X-ray film for 1-10 
minutes. 
 
2.3.4 Enzyme linked immunosorbent assay (ELISA) 
The ELISA assay was carried out as per manufacturer‘s instructions (R&D Systems). Briefly, 
flat-bottomed 96-well plates were coated overnight at room temperature with 100 μL of 
coating antibody. Plates were washed 3 times with wash/dilution buffer (0.1% Tween 20 in 




was added to the plates and incubated for 1 h before being treated with 100 μL of either 
sample or standard for 2 h at room temperature while shaking. Wells were then treated with 
100 μL of biotinylated detection antibody per well and incubated for 2 h at room temperature 
followed by 100 μL of streptavidin–horseradish peroxidase, diluted 1 in 200 diluent buffer, 
for 20 min at room temperature while shaking. After washing 2 times, 100 μL of substrate 
solution was added to each well and allowed to incubate for 30 min. The reaction was stopped 
by the addition of 50 μL of 2N sulfuric acid. The absorbance was quantified at an emission of 
450 nm with reference wavelength at 590 nm (Dynex MRX plate reader). 
 
2.3.5 RNA extraction and Real-time PCR 
2.3.5.1 RNA extraction and quantification 
After 3 days culture, cell pellets were collected by centrifugation at 445g for 5 minutes. RNA 
was isolated using the RNeasy Micro Kit (Qiagen, Manchester, UK) following the 
manufacturer‘s instructions. RNA concentration was assessed by spectrophotometry using a 
NanoDropTM 1000 spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). 
 
2.3.5.2 Complementary DNA (cDNA) Synthesis 
Depending on the number of CD4+ T cells obtained, the RNA concentration was usually 
between 10-20 ng/ μl. 12 μl RNA was used for the reverse transcriptase reaction to synthesize 
cDNA using Qiagen Quanti Tect Rev Transcription Kit. Briefly, 12 μl RNA was incubated 
with 2 μl gDNA wipe out buffer for 5 minutes at 42°C. The DNase-treated RNA was 
subsequently reverse transcribed in 20 μl reactions according to the manufacturer‘s 
instructions. cDNA synthesis was allowed to proceed for 25 minutes at 42°C before 





2.3.5.3 Real-time quantitative polymerase chain reaction (PCR)  
The expression of VDR was measured by real-time qPCR using relative quantification 
normalized to 18S rRNA. PCR was performed in 24-well PCR plates in a 20 μl reaction 
volume (2 μl of cDNA, 1μl 18s rRNA primers and probe, 1μl VDR primers and probe, 10 μl 
of Taqman PCR Master Mix and 6 μl H2O) and PCR (40 cycles) was run in the condition as 
follows: The PCR cycle parameters were 95°C for 10 minutes, 40 cycles of 95°C for 2 
seconds, and 60°C for 20 second. The PCR data were acquired and quantified by relative 
quantification (RQ) analysis RQ=2
-△△CT. RQ value showed the fold change in gene 
expression compared with control group that was normalized to 1. 
 
2.3.6 Western blot 
2.3.6.1 Protein extraction 
CD4+ T cells were centrifuged at 445g and washed with ice cold PBS twice. They were re-
suspended in 30µl of protein lysis buffer and incubated on ice for 15 min before being 
centrifuged at 445g at 4 ºC for 15 min.  The supernatant was removed, aliquoted and stored at 
-20 ºC until being used in western blot experiments. 
 
2.3.6.2 Bicinchoninic acid (BCA) protein assay 
Protein concentration was determined using Pierce™ BCA Protein Assay Kit (Thermo 
Scientific, Loughborough, UK) according to the manufacturer's manual. 10 μl of a protein 
sample was used in the assay. Samples were stored at -80ºC until used in western blot 
experiments. 
 
2.3.6.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting 




running gel and 5% stacking gel were prepared for separation (See Table 2 for the 
composition for running and stacking gel). Once set, equal amounts of proteins were loaded 
into wells and the Prism Ultra Protein Ladder (10-180 kDa) was used as molecular weight 
markers. The gel was electrophoresed at 150 V until the dye front was close to the bottom. 
After running the SDS-PAGE, the gel was transferred to a polyvinyl difluoride (PVDF) 
membrane in western blot transfer buffer for 1 h at 100V. Membrane was blocked in western 
blot blocking buffer for 1 h with shaking at room temperature before incubating with the 
primary antibody diluted in blocking buffer overnight at 4 degree. After three washes of 10 
minutes with TBST, membrane was incubated with the secondary antibody for 45-60 minutes. 
The membrane was washed 3 times with washing buffer before being developed by enhanced 
chemiluminescence (ECL). 
Table 2.2 Composition for running and stacking gels 
Running gel  
Acrylamide 30% 4ml 
Tris 1.5M pH 8.8 3ml 
H20 4.8ml 
SDS 10% 120µl 
APS 10% 54µl 
Temed 9µl 
 
Stacking gel  
Acrylamide 30% 1ml 
Tris 1.5M pH 6.8 1.25ml 
H20 2.75ml 
SDS 10% 50µl 






2.3.6.4 Stripping and re-probing of PDVF membranes 
To allow a western blot membrane to be re-probed, it was stripped using striping buffer. In 
brief, membrane was washed twice with TBST before being incubated with stripping buffer 
for 15 minutes at 56 ºC. It was then washed twice with TBST with gentle agitation and 
blocked with blocking buffer for 1 h. The membrane was then incubated with another 
antibody as previously described in section 2.5.5.2. 
 
2.3.6.5 Densitometry analysis 
Blots were scanned and densitometric analysis was carried out using ImageJ software. Full 
length of protein bands were selected manually and the net pixel intensity of the selected 
bands were measured. 
 
2.3.7 Nitrate and nitrite analysis 
Concentration of nitrate and nitrite in plasma was analyzed using Nitric Oxide Assay Kit 
(Thermo Scientific, Loughborough, UK) according to the manufacturer‘s instructions. In brief, 
plasma was diluted using Reagent Diluent provided in the kit and ultra-filtrated through a 
10,000 molecular weight cut off filter. For nitrite analysis, 50 µl of flitted plasma was 
incubated with 50 µl Griess Reagent I and Griess Reagent II for 10 min at room temperature 
and optical density of each well at 540 was detected using Dynex MRX plate reader. Nitrate 
in the plasma was converted to nitrite by incubating with NADH and nitrate reductase 
enzyme at 37 ºC for 30min before analysis. 
 
2.3.8 VitD analysis 
Concentration of 25 (OH) vitamin D in plasma was analyzed using 25(OH) Vitamin D ELISA 




2.3.9 FLG genotyping 
All patients were screened for FLG mutations and the genotyping was performed by the 
Wellcome Trust Clinical Research Facility. The two FLG mutations that were most common 
in Caucasian populations (2282del4, R501X) were tested.  R501X mutation arises from a 
1501C-to-T transition near the start of repeat 1 in exon 3 of the FLG gene. The 2282del4 
mutation leads to a premature termination codon 107 bp downstream and, like R501X, stops 
protein translation within the first filaggrin repeat. 
 
Genomic DNA was isolated from whole blood. Genotyping was performed in 384 well-plates, 
using the TaqMan polymerase chain reaction-based method. Allelic discrimination using this 
chemistry is based on the design of two TaqMan probes, specific for the wild type allele and 
the mutant allele. Each of the two probes is labelled with a different fluorescent tag (FAM and 
VIC), and each is designed with the gene mutation affecting the middle part of the probe 
sequence. The binding efficiency of the wild type TaqMan probe to the mutant allele and vice 
versa is low due to the mismatch within the TaqMan probe and the target sequence; therefore, 
mismatched binding is highly reduced.  
 
 The final volume PCR reaction was 10 μl using 20 ng of genomic DNA, 5 μl of Universal 
PCR Taqman Master Mix and 0.06μl of Primer, 0.02ul of Probe and 4.92μl of deionised water 
or 0.1μl of Primer, 0.01μl of Inner Primer, 0.02μl of Probe and 4.87uμl of deionised water. 
The cycling parameters are as follows: 95° for 10 minutes, followed by forty cycles of 
denaturation at 95° for 15 seconds and annealing/extension at 60° for 1 minute. PCR plates 
were then read on Applied Biosystems by Life Technologies QuantStudio 12K Flex Real 
Time PCR System (#285880765) instrument with QuantStudio 12K Flex Software or Taqman 




2.4 Statistical analysis 
All data are expressed as mean±SEM. Data were analyzed, where appropriate, using 
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). P value of less than 0.05 

























Chapter 3 Investigating the effect of nitric oxide on human peripheral CD4+ T cell 
differentiation and function 
 
3.1 Introduction 
UV radiation, especially the middle wavelength UVB (290nm-320nm), induces both local 
and systemic immunosuppression. It has been shown in a murine contact hypersensitivity 
(CHS) model that application of haptens on UV-exposed skin failed to induce sensitization, 
and that adoptively transferred splenocytes obtained from these animals resulted in hapten-
specific unresponsiveness in recipient animals.  Depletion of T cells from the transferred cells 
resulted in loss of suppressive activity which indicated that T cells with regulatory function 
were important in UV-induced immunosuppression (Schwarz, 2008). 
 
The phenotype of UV-induced murine antigen specific regulatory T cells has been 
characterized in the CHS model. It was demonstrated that UV-induced Treg express CD4, 
CD25, CTLA-4, dectin-2, glucocorticoid-induced TNF receptor family–related protein 
(GITR), neuropilin, and CD62L but not the ligands for the skin-homing receptors E- and P-
selectin. A small subtype of murine UV-induced Treg expressed the transcription factor 
FoxP3 (Schwarz, 2005). In vitro activation with the specific antigen induced the release of IL-
10 by UV-induced Treg, which was critically involved with the suppressive activity. 
  
NO is reported to play a key role in cutaneous physiology. Topical application of the NO 
inhibitor NG-monomethyl-L-arginine acetate (L-NMMA) resulted in a reduced level of UV 
induced immunosuppression in humans, suggesting that UV-induced NO played a role in UV 
radiation-induced immunosuppression (Kuchel et al., 2003). Skin contains large stores of 




have shown that nitrite in skin was photolysed on irradiation with UV to release NO 
(Mowbray et al., 2009). Nitrate photolysis to release NO was greatly enhanced by the thiols-
containing amino-acid cysteine, which was abundant in skin (Dejam et al., 2003). These data 
suggest that translocation of NO from skin to the circulation on exposure to UV radiation may 
contribute to the control of systemic inflammatory responses. 
 
Most of the physiological activities of NO are mediated through soluble guanylyl cyclase 
(sGC) which is the key enzyme in NO signalling pathway (Calabrese, V., C. Mancuso, et al, 
2007). NO activates sGC and in turn initiates the production of the messenger cGMP, which 
inhibits leukocyte recruitment, excessive cell proliferation and inflammation through a 
number of downstream mechanisms.  
 
The role of NO in regulatory T cells (Tregs) differentiation remains controversial. Murine 
CD4+ T cells have been reported to express iNOS upon activation, which suppressed the 
differentiation of these cells into Foxp3+Treg induced by TGFβ, although the suppressive 
function of induced Foxp3+Treg remained unaffected (Jayaraman et al., 2014). Similarly, it 
has been shown that NO inhibited Foxp3+Treg induction driven by TGFβ and promoted 
naive CD4+ T cell differentiation to Th1 in murine model (Lee et al., 2011). Furthermore, in a 
murine model of multiple sclerosis, NO produced by splenocytes from myelin basic protein-
immunized mouse decreased CD4+CD25+ and CD25+Foxp3+ population, which was further 
confirmed by using splenocytes from iNOS knock out mice. The effect of NO on Foxp3 
expression was mediated by soluble guanylyl cyclase-mediated production of cGMP 
(Brahmachari and Pahan, 2010).  
 




differentiation, there are also reports suggesting that NO is involved in Treg induction in mice. 
Systemic NOS inhibition using L-NG-nitro arginine methyl ester (L-NAME) decreased Treg 
in circulation (Brinson et al., 2013). Exogenous NO could induce the generation of a type of 
regulatory T cell (NO-Treg) from murine naive CD4+ T cells that did not express Foxp3 but 
secreted IL-10 and required cell-cell contact for its suppressive effect (Niedbala et al., 2007). 
Stimulation of CD4+ T cells by allogeneic bone marrow-derived dendritic cells (DC) in the 
presence of IFN-γ resulted in Treg induction. This effect was abolished by NOS inhibition 
and could be replicated by provision of an exogenous NO donor, which clearly indicated the 
involvement of NO in this process (Feng et al., 2008).  
 
These results highlight the complex role of NO in murine Treg induction, but no conclusive 
data exist so far on the effect of NO on human Treg differentiation. A previous study reported 
that similarly to murine CD4+ T cells, iNOS expression in human CD4+ T cells also inhibited 
Foxp3 expression and Treg induction driven by TGFβ (Jayaraman et al., 2014). In contrast, 
Niedbala et al reported that NO-Treg were induced by NO from human peripheral CD4+ T 
cells (Niedbala et al., 2007). 
 
As understanding the mechanisms governing Foxp3+ Treg induction is important for AD 
treatments, this chapter describes experiments designed to determine the role of NO in the 









Chapter hypothesis and research questions 
 
NO contributes to the clinical efficacy of NB-UVB phototherapy in AD through their effects 
on the function of regulatory T cells either directly or indirectly through its action on antigen 
presenting cells. 
 
 Does NO induce functional regulatory T cells from human peripheral CD4+ T cells? 





















3.2.1. NO modulates human peripheral CD4+ T cell phenotype. 
NOC-18 is a NO donor which releases NO at a slow rate with a half-life of 20h. NOC-18 is 
widely used in in vitro and in vivo experiments investigating the effects of prolonged, 
constant NO delivery to cells and tissues. It is reported that NOC-18 at 100-200 µM releases 
200-400 nM NO which is considered to be the pathological concentration of NO in tissue 
reported during inflammation and infection (Niedbala et al., 2007). The physiological 
concentration of NO range is between 100pM to 5nM. Depending on NO donors, the 
functional changes elicited by the generation of NO from iNOS can be comparable to what is 
observed with millimolar concentrations of NO donors under in vitro conditions (Katagiri et 
al ., 2003). 
 
We first investigated the effect of NOC-18 on the phenotype of CD4+ T cells. To determine 
the optimal concentration for NOC-18, human peripheral blood CD4+ T cells were purified 
and cultured with plate bound anti-CD3 and anti-CD28 antibodies in the presence of different 
concentrations of NOC-18 for 5 days as described in Chapter 2.3.1.2. Activated CD4+ T cells 
treated with vehicle was used as control. The forkhead transcription factor Foxp3 is highly 
expressed on human CD25+ regulatory T cells and is critical for their development and 
function (Ziegler, 2006). Therefore, the expression of CD25 and Foxp3 were analysed by 
flow cytometry. Results showed that NOC-18 at 100 µM had the strongest inducing effect for 
CD25+Foxp3+ T cells. 100 µM NOC-18 did lead to a slight decrease in cell viability but this 
was of less than 10% indicating that the large majority of cells were still viable after 5 days 






As shown in Figure 3.1 c & d, neither the overall expression level (MFI) of CD25 nor the 
CD25+% were affected by NO indicating that T cell activation was not affected. Although 
FoxP3 protein is the most specific marker of Treg cells to date, studies have shown that 
Foxp3 is expressed in CD25low and CD25 negative CD4+ T cells and some CD8+ T cells 
(Ziegler, 2006). Activated effector T cells transiently express Foxp3, but at a level which is 
significantly lower than that on Tregs and is not associated with suppressive function.  Other 
biomarkers are required to identify human Tregs. Foxp3 has been reported to interact with 
CD127 promoter and suppress the expression of CD127 on human Tregs (Liu, W., et al, 2006). 
CD4+CD127lo/- cells isolated from human peripheral blood remain anergic and suppress 
alloantigen responses in vitro (Liu et al., 2006). Therefore, the NO effect on 
CD25+Foxp3+CD127lo/- cells was analysed. As shown in Figure 3.1 e & f, the frequency of 
CD25+ Foxp3+ CD127- T cells and the MFI of Foxp3 on CD25+ Foxp3+CD127- T cells 
were significantly increased by NO, which indicated that NO promoted the development of 
cells with a conventional Treg phenotype. Cutaneous lymphocyte-associated antigen (CLA) is 
reported to be expressed on T cells that are specific for skin associated antigens and is 
considered as a skin homing marker (Bos et al., 1993). CLA expression on CD25+ Foxp3+ 
CD127- T cells was also significantly increased by NO (Fig 3.1 g). In support of this, the 
frequency of CD25+Foxp3+CD127- Tregs within the CLA+ CD4+ T cells was also increased 
by NOC18, while there was no significant effect of NO on the proportion of CLA+ T cell of 
total CD4+ T cells, suggesting that NO promoted differentiation of Tregs that were able to 
migrate to the skin (Fig 3.1 h&i).  
 
To further confirm that the modulation of T cell phenotype was induced by NO released from 
NOC-18 and not caused by the backbone of the chemical, a different NO donating compound 




on the frequency of CD25+Foxp3+CD127- cells, and the level of Foxp3 and CLA expression 
as shown in Fig 3.1 j-l, which confirmed that the phenotype changes observed were most 
likely induced by NO.  
 
To further investigate whether sustained release of NO was required for CD4+ T cell 
phenotype modulation, CD4+ T cell were activated and treated with 100µM NOC-18. The 
culture medium containing 100 µM NOC-18 was taken out at different time points and fresh 
RPMI culture medium was added in to culture wells after the cells had been washed with PBS 
once. As shown in Fig 3.2 a&b, NO had to be present for at least 24 h to have effect on 
CD25+Foxp3+CD127- cell induction and CLA expression. Taken together, these results 
suggested that sustained exposure to NO at the levels reported in inflammation induced 
human Tregs that have enhanced ability to migrate to skin. 
 














Fig 3.1 NO modulates human peripheral CD4+ T cell phenotype. Purified peripheral CD4+ T cells 
were activated with plate bound anti CD3/28 and treated with NO-donating compound for 5 days. T cell 
phenotype was measured by flow cytometry. a) Percentage of CD25+Foxp3+ cells of activated T cells after 
being treated with different concentrations of NOC-18. b) Viability of total cells after being treated with 
100 µM NOC-18 (N=7). c-d) Geometric mean of CD25 expression and percentage of CD25+ cells on total 
CD4+ T cells (N=7). e-g) Percentage of CD25+Foxp3+CD127- cells of activated T cells, Foxp3 and CLA 
expression on CD25+Foxp3+CD127-T cell after total CD4+ T cells being treated with 100µM of NOC-18 




CLA+ T cells of total cells after being treated with 100 µM of NOC-18 (N=6). j-l) Representative results of 
percentage of CD25+Foxp3+CD127- cells of activated T cells, Foxp3 and CLA expression on 
CD25+Foxp3+CD127-T cell after total CD4+ T cells being treated with 100µM of DETA-NO. 




Fig 3.2 Sustained NO is required to modulate CD4+ T cell phenotype. Purified peripheral CD4+ T cells 
were activated with plate bound anti CD3/28 and treated with 100 µM NOC-18. NOC-18 containing 
medium was replaced with fresh culture medium at the indicated time points and T cell phenotype was 
measured by flow cytometry at Day5. CD4+ T cells that have been treated with100 µM NOC-18 for 5 days 
were used as positive control.  a) Percentage of CD25+Foxp3+CD127- cells in the activated T cells (N=2). 





3.2.2 NO modulates CD4+ T cell phenotype via cGMP dependent pathways. 
To investigate whether the effect of NO on CD4+ T cell phenotype depended on the sGC-
cGMP signalling pathway, CD4+ T cells were cultured as above with 100µM NOC-18 in the 
presence or absence of a specific competitive inhibitor of cGMP activation, 1-H-oxodiazolo-
[1,2,4]- [4,3-a]quinoxalin-1-one (ODQ). Fig 3.3 showed that ODQ blocked the effect of NO 
on the frequency of CD25+ Foxp3+CD127- T cells in a dose dependent manner (Fig 3.3 a&b) 
These data demonstrated that NO modulated the phenotype of CD4+ Tcells via c-GMP 
dependent pathways. 
  
Fig 3.3 NO modulates CD4+ T cell phenotype via both cGMP dependent pathways. Purified peripheral 
CD4+ T cells were activated with plate bound anti CD3/28 and treated with 100µM NOC-18 in the 
presence of different concentrations of ODQ. T cell phenotype was measured by flow cytometry at Day5. a) 




100µM NOC-18 in the presence of different concentrations of ODQ.  b) Percentage of 
CD25+Foxp3+CD127- cells of activated T cells normalized to respective control (N=3). 
  
3.2.3 NO induces CD25+ Foxp3+ CD127- T cells from CD4+CD25lo T cells. 
It has previously been shown that NO inhibited proliferation of CD4+ T cells (Bogdan, C, 
2001).  Therefore, it was possible that the increased frequency of CD25+ Foxp3+ CD127- T 
cells reflected decreased expansion of Foxp3- T cells. To assess this possibility, the 
proliferation of Foxp3+ and of Foxp3- cells was assessed. CD4+ T cells were stained with the 
proliferation dye ef670 before being activated and treated with 100µM NOC-18 for 5 days as 
described in Chapter 2.3.2.4. Proliferation and phenotype of CD4+ T cells were analysed by 
flow cytometry. As shown in Fig 3.4a, NO inhibited the proliferation of total CD4+ T cells as 
reported before although it did not reach significant. However, proliferation of the Foxp3+ 
cells was inhibited to a similar extent as the Foxp3- fraction. No significant difference in 
proliferation was observed between the Foxp3- and Foxp3+ fractions (Fig 3.4b) indicating 
that the increased frequency of CD25+ Foxp3+ CD127- T cells was not caused by a 
decreased number of CD25- T cells. 
 
                 
Fig 3.4 NO inhibits Fopx3+ and Foxp3- cell proliferation to a similar extend.  Purified CD4+ T cells 




with 100 µM NOC-18 for 5 days. T cells proliferation and phenotype was analysed by flow cytometry. a) 
Proliferation of total CD4+ T cells after being treated with 100 µM NOC-18 for 5 days. b) Proliferation of 
Foxp3+ and Foxp3- cell population after being treated with 100 µM NOC-18 for 5 days. 
 
To further confirm the effect of NO on Treg proliferation in our model, CD4+ T cells were 
labelled with ef670and activated with anti-CD3/28 in the presence of 100 µM NOC-18, and 
Foxp3 expression and proliferation of CD4+T cells were analysed. As shown in Fig 3.5, by 
day 5, there was a marked increase in the proportion of Foxp3+ cells and, importantly, the 
majority of these had lower ef670 staining, confirming a close correlation between Foxp3 
enrichment and proliferation. 
 
                
 
Fig 3.5 Increased frequency of CD25+ Foxp3+ CD127- T cells involves Foxp3+ T cells proliferation. 




CD3/28 and treated with 100µM NOC-18 for 5 days. Foxp3 expression and T cell proliferation were 
analysed by flow cytometry. Representative FACS plot showing Foxp3 versus proliferation of total CD4+ 
T cells at Day 5 (N=3). 
 
 These data suggested that NO could either promote the proliferation of pre-existing nTreg, or 
induce expression of Foxp3 in Foxp3- CD4+ T cells, or both. To check whether NO induced 
expansion of Foxp3+ nTreg circulating in blood leading to increased frequency of 
CD25+Foxp3+CD127- T cells, CD4+CD25hi cells were isolated from total CD4+ T cells and 
cultured in the presence of 100µM NOC-18 for 5 days as described in Chapter 2.2.5. After 
enrichment, CD4+CD25hi % was increased to 48.2% compared with 4.5% in total CD4+ T 
cells as shown in Fig 3.6a. Although the percentage of CD25+Foxp3+CD127- T cells was 
also increased by NO from CD4+CD25hi cells (Fig 3.6b), it was difficult to conclude where 
the Foxp3+ cells came from since the purity for the CD4+CD25hi cells was only ~30%. 
 
We next asked if the increased frequency of CD25+Foxp3+CD127- T cells was induced from 
the CD25lo T effector cell population. Therefore, CD25hi cells were depleted from the total 
CD4+ T cells (Fig 3.6c) and the CD25lo cells were cultured with 100µM NOC-18 for 5 days. 
As shown in Fig 3.6d, CD25+Foxp3+CD127- cells were induced from CD25lo cells after 
being activated for 5 days. NO significantly increased the frequency of 
CD25+Foxp3+CD127- cells from activated CD25lo cells and expression of CLA was also 
increased by NO on the induced Foxp3+ T cells (Fig 3.6 d&e). Taken together, these results 
suggested that NO promoted CD25+ Foxp3+ CD127- T cells differentiation from 








Fig 3.6 NO promotes CD25+ Foxp3+ CD127- T cells differentiation from CD4+CD25lo T cells. 
CD25hi and CD25lo cells were isolated from peripheral CD4+ T cells and were activated and cultured with 
100µM NOC-18 for 5 days. T cells phenotype was analysed by flow cytometry. a) Representative FACS 
plot showing CD25 versus CD127 of total CD4+ T cell and CD25hi cells before and after enrichment. b) 
Percentage of CD25+Foxp3+CD127- cells of activated T cells after CD25hi T cells being treated with 
NOC-18 for 5 days (N=3). c) Representative FACS plot showing CD25 verses CD127 of total CD4+ T cell 
and CD25lo cells before and after depletion. d-e) Percentage of CD25+Foxp3+CD127- cells of activated T 
cells (N=6) and CLA expression on CD25+Foxp3+CD127- cells after CD25lo T cells (N=5) being treated 
with NOC-18 for 5 days. P value was calculated using Wilcoxon matched pairs T test. 
 
3.2.4 NO induced CD25+Foxp3+CD127- cells have immune-regulatory function. 
To next assess whether CD25+Foxp3+CD127- cells induced by NO have immune-regulatory 
function, I performed functional suppression assays. CD4+ T cells were divided into two 




100µM NOC-18 for 5 days, which were used as suppressor cells in the following experiments 
(NO-CD4). The other part was frozen in -80 degree on the same day of isolation. After 5 days, 
the frozen cells were thawed, stained with proliferation dye ef670 and used as responder cells, 
which were cultured together with unlabelled suppressor cells at different ratios. Based on 
staining of ef670, the responder cells could be separated from the suppressor cells, and their 
proliferation was analysed by flow cytometry.  
 
As shown in Fig 3.7a and b, 71.8% of responder cells proliferated when they were cultured 
alone without suppressor cells. Based on the results shown in Fig 3.1, approximately 20% of 
the total CD4+ cells were CD25+Foxp3+CD127- after being cultured with 100µM NOC-18 
for 5 days. Therefore, in order to achieve a responder cell : Foxp3+ cell ratio of 1:1 and 1:2, 
responder cells were mixed with total CD4+ T cells that were cultured with NOC-18 for 5 
days (NO-CD4) at ratios of 1:5 and 1:10. When the responder cells were co-cultured with 
NO-CD4 at 1:5, their proliferation decreased and further decreased when the responders and 
NO-CD4 ratio increased to 1:10 (Fig 3.7a and b). Thus NO-CD4 T cells significantly 
inhibited the proliferation of autologous CD4+ T cell in a dose-dependent manner. To confirm 
that suppression of proliferation was not due to nutrient deprivation caused by increased 
number of cells cultured in one well, control CD4+ T cells that had been activated for 5 days 
without NOC-18 were co-cultured together with responder cells and proliferation of the 
responder cells were analysed. As shown in Fig 3.7c, the proliferation of responder cells were 
increased when co-cultured with activated CD4+ T cells at 1:5 ratio. The proliferation of 
responder cells were slightly decreased by activated CD4+ T cells at 1:10 ratio although the 
changes were relatively small compared with that caused by NO-CD4. The expansion of 
existing nTreg in CD4+ T cells might contribute to this effect which also indicated that Treg 





                                  
Fig 3.7 NO-CD4 T cells significantly inhibit the proliferation of autologous CD4+ T cell in a dose-
dependent manner. Purified CD4+ T cells were activated with plate bound anti-CD3/28 and cultured with 
100µM NOC-18 for 5 days (NO-CD4). Autologous CD4+ T cells were used as responder cells and cultured 
with NO-CD4+ T cells at different ratios for 4 days. Proliferation of responder cells was analysed by flow 
cytometry. a) Representative FACS plot showing proliferation of responder cells cultured with NO-CD4 T 
cells. b) Proliferation of responder cells cultured with NO-CD4 T cells at different ratios at Day4 (N=6) c) 
Representative FACS plot showing proliferation of responder cells cultured with total CD4+ T cells that 




experiments. P value was calculated by Friedman test followed by Dunns post test. 
 
To further confirm that CD25+Foxp3+CD127- cells within the NO-CD4 cells were 
responsible for the suppressive function, CD25hi cells (NO-CD25hi) were isolated from 
CD4+ T cells that have been activated and treated with 100µM NOC-18 for 5 days as 
described in Chapter 2.2.5. Purity of NO-CD25hi cells was analysed after isolation, which 
showed that NO-CD25hi cells also expressed high level of Foxp3 (Fig 3.8 a). NO-CD25hi 
cells were used as suppressor cells and co-cultured with responder cells at different ratios. 
Compared with NO-CD4 T cells, NO-CD25hi showed higher efficiency in inhibiting 
autologous CD4+ T cell proliferation, while the proliferation of responder cells was inhibited 
more than 50% when responder and NO-CD25hi were cultured at 2:1 ratio (Fig 3.8b). Taken 
together, these results indicated that NO induced functional Foxp3+ regulatory T cells in total 
CD4+ T cells and in CD4+CD25- T cells.  
 
Fig 3.8 NO induced CD25+Foxp3+CD127- cells inhibit proliferation of autologous CD4+ T cell in a 




CD3/28 and treated with 100µM NOC-18 for 5 days (NO-CD25hi). NO-CD25hi cells were co-cultured 
with autologous CD4+ T cells at different ratios for 4 days and proliferation of autologous CD4+ T cells 
were analysed by flow cytometry. a) Representative FACS plot showing CD25 verses Foxp3 of NO-CD4 T 
cells and NO-CD25hi cells before and after isolation. b) Proliferation of responder cells cultured with NO-
CD25hi T cells at different ratios at Day 4. Representative result of 6 separate experiments.  
 
3.2.5 Immuno-suppression of NO-induced Foxp3+Treg depends on cell-cell contact. 
It has been reported before that cell-cell contact plays a non-redundant role in Treg mediated 
immune suppression. To assess whether NO-induced Foxp3+Tregs exert their regulatory 
function through cell-cell contact, I performed transwell experiments. As described in Chapter 
2.3.2.6, responder cells were seeded at bottom of 24-well plate and activated with anti-
CD3/28. Total CD4+ T cells that had been treated with 100µM NOC-18 for 5 days (NO-CD4) 
were used as suppressor cells in this experiment and they were cultured in the upper chamber 
of the transwell. As shown in Fig 3.9 a&b, NO-CD4 Tcells inhibited the proliferation of 
responder cells as showed above. The use of transwells prevented the suppressive function of 
NO-CD4 on proliferation indicating that NO-induced Foxp3+ Treg required cell-cell contact 
for their regulatory function.  
 
Besides cell-cell contact, cytokines with suppressive functions such as IL-10 derived from 
Tregs have been implicated as important mediators of the suppressive function of Tregs. 
Therefore, the concentrations of the anti-inflammatory cytokine IL-10 and pro-inflammatory 
cytokine IFNγ in the cell culture supernatants from CD4+ T cells cultured with or without 
100µM NOC-18 were determined by ELISA. As expected, both IL-10 and IFNγ secretion 
were decreased by NO since the proliferation of CD4+ T cells were inhibited by NO. The 





To further investigate the potential role of suppressive cytokines in NO-CD4 mediated 
immune suppression, culture supernatants from CD4+ T cells cultured with or without 
100µM NOC-18 for 5 days were mixed with fresh RPMI at different ratios and the mixtures 
were added to cultures of ef670-labeled responder T cells and proliferation of responder cells 
was analysed by flow cytometry. In contrast to the results obtained using the transwells, the 
proliferation of responder cells was not affected by the culture supernatants (Fig 3.10 d & e). 
These data suggested that the cytokines secreted by NOC-18 treated CD4+ T cell were not 






Fig 3.9 NO-induced Foxp3+ Tregs require cell-cell contact for its suppressive function. Purified CD4+ 
T cells were activated with anti-CD3/28 and treated with 100µM NOC-18 for 5 days (NO-CD4), which 
were used as suppressor cells. Suppressor cells were seeded either together with autologous CD4+ T cells 
or seeded in the upper well of transwell to be physically separated from autologous CD4+ T cells. 
Proliferation of autologous CD4+ T cells were analysed by flow cytometry. a) Representative FACS plot 
showing proliferation of autologous CD4+ T cells cultured with NO-CD4 at different ratios with or without 
transwell for 4 days. b) Proliferation of autologous CD4+ T cells after being co-cultured with NO-CD4 at 
1:10 ratio in the presence or absence of transwell for 4 days (N=4). P value was calculated by Friedman test 




              
 
Fig 3.10 IL-10 secreted by NO-induced Foxp3+ Tregs is not sufficient for their suppressive function. 
Culture supernatants from CD4+ T cells cultured with or without 100µM NOC-18 for 5 days were mixed 
with fresh RPMI at different ratios and the mixtures were transferred to ef670-labeled autologous CD4+ T 
cells. Proliferation of autologous CD4+ T cells was analysed by flow cytometry. a-c) IL-10 and IFNγ 
concentration and IL-10/ IFNγ ratio in the culture supernatant of CD4+ T cells being activated with 
CD3/28 and treated with 100 µM NOC-18 for 5 days (N=4). d) Proliferation of autologous CD4+ T cells 
after being cultured using mixed culture medium for 4 days.  
 
3.2.6 Multiple pathways mediate the immuno-regulatory function of NO-induced 
Foxp3+Treg. 
Apart from IL-10 signalling, multiple signalling pathways have been reported to be utilized 
by Foxp3+Tregs to exert their regulatory function. The most commonly reported of these are 
membrane bound TGFβ, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed 




Foxp3+Tregs suppressive function, I blocked each of these pathways using either chemical 
agents or blocking antibodies. I used the compound SB-431542 (SB), a competitive ATP 
binding site kinase inhibitor that inhibits TGFβ signalling pathway, and antibodies that block 
PD-1 and its ligand PD-L1 and CTLA-4. Purified CD4+ T cells were activated with plate 
bound anti-CD3/28 and treated with 100 µM NOC-18 for 5 days to generate NO-Foxp3+Treg. 
CD25hi cells (NO-CD25hi) were isolated and co-cultured with autologous CD4+ T cells for 4 
days in the presence or absence of the compound/antibodies mentioned above. The 
proliferation of autologous CD4+ T cell was then analysed by flow cytometry. 
 
As shown in Fig 3.11a, NO-CD25hi cells inhibited the proliferation of autologous CD4+ T 
cells as expected. The inhibition was partially prevented in the presence of the TGFβ 
signalling inhibitor SB. Antibodies blocking PD-1/PD-L1 also partially reversed the 
inhibitory effect of NO-CD25hi on the proliferation of autologous CD4+ T cells. However, 
neither of these pathways could fully reverse the inhibitory effect of NO-CD25hi. Therefore, 
to test whether there was any synergistic effect of these pathways, autologous CD4+ T cells 
were co-cultured with NO-CD25hi while both TGFβ and PD/PD-L1 signalling pathways 
were blocked. No synergistic effect was seen when both pathways were blocked (Fig 3.11a).  
As shown in Fig 3.11b, blocking CTLA-4 did not affect the inhibitory function of NO-
CD25hi. Taken together, these data suggested that both TGFβ and PD-1 signalling pathways 
were independently involved in mediating the immunosuppressive function of NO induced 
Foxp3+Tregs but that neither were sufficient to account for the entire suppression seen. Other 





     
Fig 3.11 Multiple pathways mediate immune-regulatory function of NO-induced Foxp3+Treg. 
CD25hi cells (NO-CD25hi) were isolated from total CD4+ T cells that have been activated and treated with 
100 µM NOC-18 for 5 days. NO-CD25hi were co-cultured with autologous CD4+ T cell for 4 days in the 
presence of TGFβ signalling inhibitor SB, antibodies blocking PD-1 and its ligand PD-L1 and CTLA-4. 
Proliferation of autologous CD4+ T cells were analysed by flow cytometry. a) Representative FACS plot  
showing proliferation of autologous CD4+ T cells cultured with NO-CD25 at Day4 in the presence of 
TGFβ signalling inhibitor SB (representative result of 6 separate experiments).), antibodies blocking PD-1 
and its ligand PD-L1(representative result of 6 separate experiments.) or together (representative result of 3 
separate experiments.). b) Representative FACS plot showing proliferation of autologous CD4+ T cells 






3.2.7 NO modulates differentiation of human monocyte-derived dendritic cells (mo-DCs). 
DCs have unique capacity to process antigen, present it to CD4+ T cell and shape the 
differentiation of naive CD4+ T cells. To investigate whether NO could affect CD4+ T cell 
differentiation indirectly through affecting DC function, I analysed the effect of NO on 
human mo-DCs differentiation and maturation. CD14+ monocytes were isolated from 
PBMCs and cultured with GM-CSF and IL-4 for 6 days to allow them to differentiate into 
immature mo-DCs as described in Chapter 2.3.1.1. The immature mo-DCs were matured in 
the presence of Poly I/C for 48 h and the phenotype of both immature and mature mo-DCs 
was analysed by flow cytometry.  Compared with immature DCs which expressed medium 
level of CD86 and low level of CD80, matured mo-DCs expressed high levels of CD80 and 
CD86 indicating that the protocol used to differentiate and maturate mo-DCs worked (Fig 
3.12 a). As shown in Fig 3.12 b, NO significantly decreased the expression of antigen-
presenting molecule HLA-DR and slightly decreased the expression of co-stimulatory 
molecule CD86 on immature mo-DCs as previously reported (Bogdan, C, 2001). The other 
markers tested on immature mo-DC were not affected by NO. None of the markers analysed 
were modified by NO on mature mo-DCs (Fig 3.12 c). Taken together, these results indicated 
that NO may affect the differentiation of mo-DCs which indicated that NO may also affect 










Fig 3.12 NO modulates differentiation of human monocyte-derived dendritic cells (mo-DCs). CD14+ 
monocytes were isolated from PBMCs and cultured with cytokines including GM-CSF and IL-4 for 7 days 
with or without 100µM NOC-18 to generate immature mo-DCs. The immature mo-DCs were matured Poly 
I/C for 48 h and phenotype of both immature and mature mo-DCs were analysed by flow cytometry. a) 




and expression of antigen-presenting molecules, costimulatory molecules and maturation molecules on 
immature mo-DCs (N=7).  c) Expression of antigen-presenting molecules, costimulatory molecules and 
maturation molecules on mo-DCs matured with Poly I/C for 48h (N=6).  P value was calculated using 

























3.3 Discussion  
Extensive studies have revealed the substantial heterogeneity of Tregs in both mice and 
humans. In addition to nTregs, Tregs can be induced from CD4+CD25- T cells by specific 
antigens in humans and mice. Several other types of Tregs have also been reported such as 
type 1 Tregs which do not express Foxp3 and mediate their suppressive function through IL-
10, whereas Tregs induced by TGF-β modulate immune responses by secreting TGF-β and 
IL-10 (Sakaguchi et al., 2008). Previous murine studies have shown that a new type of Treg 
(NO-Treg) was induced from CD4+CD25- T effector cells which was CD4+CD25-, Foxp3-, 
GITR+, CD27+, with a Th2 phenotype and the ability to ameliorate inflammatory diseases in 
a contact dependent and IL-10 dependent manner. The induction of NO-Treg did not involve 
NO-cGMP signalling pathway (Niedbala et al., 2007). 
 
Here, I have shown that NO modulated the phenotype and function of human peripheral 
CD4+ T cells, which was distinct from its reported effect on murine CD4+ T cells in several 
important aspects. The cell population induced by NO from human peripheral total CD4+ T 
cells and CD4+CD25- effector T cells was CD25+ Foxp3+ CD127-, which phenotypically 
represented Tregs. This effect could be blocked by a selective soluble guanylate cyclase (sGC) 
inhibitor indicating the involvement of cGMP. NO also affected CLA expression on 
CD25+Foxp3+CD127- cells which may affect the skin-homing ability of these cells. NO-
induced CD25+ Foxp3+ CD127- cells inhibited the proliferation of autologous CD4+ T cells 
in a contact dependent manner, the effect of which was mediated by membrane bound TGFβ 
and PD-1/PD-L1; whereas anti-inflammatory cytokines secreted by NO treated CD4+ T cells 
were not sufficient. This was further confirmed by analysing cytokines in the culture 
supernatant from NO treated CD4+ T cells in which NO decreased IL-10 and led to a 




Foxp3+Tregs from human peripheral CD4+ T cells. 
 
It is reported that 100µM of NOC-18 slowly releases 200nM NO with a half-life of 20h. The 
200nM dose of NO used here is likely to occur in vivo in sites of inflammation and has been 
used routinely in mouse in vitro experiments. During inflammation, NO could be produced 
locally at the site of inflammation or in the lymphoid organs as a consequence of the 
production and stimulatory effects of pro-inflammatory cytokines (such as IFNγ). 
Foxp3+Tregs induced by NO may control inflammation by reducing proliferation of effector 
T cells and possibly the secretion of pro-inflammatory cytokines, which forms a negative 
feedback loop.  
 
It is well known that NO inhibits endothelial activation and surface expression of vascular 
cell adhesion molecule-1 (VCAM-1) and E-selectin, in human endothelial cells stimulated 
with inflammatory cytokines. The expression of E-selectin on dermal endothelial cells has 
been proposed to be important in skin inflammatory responses (Sakaguchi et al., 2008). 
Previous study has shown that a nitric-oxide derivative of prednisolone reduced leukocyte 
adherence to endothelial cells in colitis mouse model which contributed to its anti-
inflammatory effect (Fiorucci, Antonelli et al. 2002). The importance of migratory behaviour 
of Tregs in controlling inflammation has been reported before. In a murine model of CHS, 
UV radiation-induced Tregs could only inhibit the induction but not the elicitation phase of 
CHS when injected i.v into sensitised mice due to the lack of ability of Tregs to migrate to the 
skin (Schwarz el al., 2004). Thus, increased expression of CLA on NO-induced 
CD25+Foxp3+CD127-Tregs from human peripheral CD4+ T cells could compensate for the 





In a murine model of MS, NO-Treg have been shown to be effective in treating established 
inflammation (Niedbala et al., 2013), demonstrating that Tregs generated ex vivo have 
significant potential as cellular therapeutics. Therefore, understanding the underlying 
mechanisms responsible for NO-induced Treg generation from peripheral human CD4+ T 
cells will have potential influence in optimizing protocols for clinical use. Although it is well 
known that NO inhibits proliferation of CD4+ T cells, no previous studies have shown 
whether NO selectively inhibits effector T cell or Treg proliferation.  Here we have shown 
that proliferation of both effector T cells and Tregs were inhibited by NO to a similar extend, 
which suggested that the enrichment of CD25+Foxp3+CD127- Treg cells could not be 
explained by decreased proliferation of non-Treg cells or selective expansion of Treg.  
Alternatively, a previous murine study reported that NO induced by exogenous IFN-γ from 
allogeneic GM-CSF/TGF-β-conditioned immature DC resulted in overall selection for Tregs 
via proliferation and conversion of non-Treg precursors (Feng et al., 2008). In keeping with 
this, the majority of NO-induced Foxp3+ cells were proliferating cells. However, it is not 
possible to determine whether the enrichment shown in Fig 3.5 is due to direct conversion of 
Foxp3– cells or expansion of a small starting population of Foxp3+ cells contained in the total 
CD4+ T cell. To test if NO converts circulating non-Treg cells to cells with a Treg phenotype, 
nTreg depleted CD25lo/- T cells were activated and cultured in the presence of NO.  NO 
induced CD25+Foxp3+CD127- cells, indicating that NO is able to promote differentiation of 
CD25+Foxp3+CD127- cell from CD25lo/- T cells. I also tested whether NO promotes 
expansion of Foxp3+ nTregs circulating in blood by isolating CD25hi T cells from total 
CD4+ T cells. Due to the purity issue of the CD25hiCD127lo/- cells isolated from peripheral 
CD4+ T cells, the possibility that NO induced the expansion of nTreg within the blood could 
not be ruled out. Despite this, Foxp3 expression is related with Treg differentiation and 




functionally suppressive Tregs (Fontenot et al., 2003). As shown in Fig 3.1f, the increased 
expression of Foxp3 on NO-induced CD25+Foxp3+CD127- cells suggested they may have 
higher immune regulatory capacity.  Lastly, it is reported before that NO mediates UV-
induced immune suppression by inhibiting DC function (Yuen et al., 2002). Consistent with 
these previous findings (Bogdan, 2001), NO significantly decreased  HLA-DR and slightly 
decreased CD86 expression on immature mo-DC. Therefore, the possibility that NO also 
contributed to Foxp3+Treg induction indirectly could not be ruled out. Taken together, these 
data indicated that the enrichment of Foxp3+CD127- T cells by NO involved conversion of 
CD25lo/- cells and Treg proliferation. 
 
Foxp3+ Tregs have been reported to utilize a number of mechanisms to exert their 
immunosuppressive function. Both in vitro and in vivo studies have proved that membrane-
bound TGFβ was critical for nTreg function (Gandhi et al., 2010). Following a post-
translational maturation, the amino terminal domain of TGFβ binded non-covalently with 
latency-associated peptide (LAP), which was a pro-peptide, forming an inactive form of TGF-
β. Nakamura et al showed that mouse CD4+LAP+ Tregs exerted their suppressive function 
via a TGFβ–dependent manner and were effective in suppressing autoimmunity in a murine 
model of multiple sclerosis (Nakamura et al., 2004). Chen et al showed that responder cells 
up-regulated  the expression of TGFβ receptor type II after being activated through TCR, 
which provided the opportunity for suppressor derived TGFβ to bind to activated responder 
cells and transduced suppressive signals via contact-dependent manner, as evidenced by the 
increased phosphorylation of Smad2/3 in responder cells upon contact with suppressor cells 
(Chen and Wahl, 2003). Therefore, the compound SB431542 was used to target the TGFβ 
signalling pathway. This compound acts as competitive ATP binding site kinase inhibitor 




of SMAD2 and SMAD3. Addition of SB431542 partially reversed the inhibition of 
proliferation caused by NO-induced CD25hi cells. The partially reversed inhibition indicated 
that membrane bound TGFβ is not the only mechanism utilized by NO-induced Foxp3+ Tregs. 
Besides membrane bound TGFβ, CTLA-4 and PD-1 are two key negative regulatory 
molecules that critically affect peripheral T-cell function. Active form of membrane bound 
TGFβ  and TGFβ  receptor type II expression on CD4+CD25+ suppressor T cells were up-
regulated by CTLA-4 ligation, which suggested that it was possible that these pathways may 
work together to control inflammation. Here, I have shown that addition of antibodies 
blocking PD-1/PD-L1 also partially reversed the inhibition of proliferation caused by NO-
CD25hi while blocking CTLA-4 did not have any effect, which was in consist with previous 
studies showing that NO-Tregs induced in mice did not require CTLA-4 but IL-10 for their 
suppressive function. Both membrane bound TGFβ and PD-1/PD-L1 pathways partially 
reversed the inhibitory effect of NO-induced Foxp3+ Tregs, however, neither of them played 
a dominant role. To further analyse whether there was addictive effect for these two pathways, 
NO-CD25hi cells were co-cultured with effector T cells in the presence of both TGFβ 
signalling inhibitor SB431542 and antibodies blocking PD-1/PD-L1. No synergistic effect 
was observed, which further confirmed that NO-induced Foxp3+ Treg use multiple pathways 
to exert its regulatory function to meet the challenges from distinct subsets of effector cells or 
in different tissues. The differential expression patterns of the CTLA- 4 and PD-1 led to the 
hypothesis that PD-1 controlled T cell function in tissue-specific sites due to its constitutive 
expression and CTLA-4 controls T cells in lymphoid tissue due to B7 expression on APC. 
Gene expression profiling of CD4+ T cell co-stimulated with PD-1 and CTLA-4 showed that 
PD-1 had stronger inhibitory effect than CTLA-4 on T cell activation (Francisco et al., 2010). 
Considering the enhanced expression of skin homing marker CLA on NO-induced 




these results suggested that systemically increased NO generated by UV irradiation may also 




 NO induces Foxp3+Tregs with enhanced potential skin-migrating ability from human 
peripheral CD4+ T cells via c-GMP dependent ways. 
 
 NO induced Fopx3+Tregs involves conversion of CD4+CD25- cells to 
CD25+Foxp3+CD127- cells and Fopx3+ T cells proliferation.  
 
 The suppressive function of NO-induced Foxp3+Treg requires cell-cell contact and is 
mediated by multiple pathways including PD-1/PD-L1 and membrane bound TGF-β 















Chapter 4 Investigating the effect of cis-urocanic acid on the differentiation and 
function of human peripheral CD4+ T cells and monocyte-derived dendritic cells  
 
4.1 Introduction 
Urocanic acid (UCA), located in the stratum corneum, is a major epidermal chromophore. 
UCA is also suggested to play a role in UV-induced immunosuppression (Beissert and 
Schwarz, 2002). It is a breakdown product of filaggrin produced by histidase, and isomerises 
from trans-UCA to cis-UCA after UV radiation. Cis-UCA acts as a constitutive photo 
protectant that can reduce UV radiation induced deleterious effect by 33% (Gibbs and Norval, 
2011). The isomerisation takes place at 300–315 nm in mouse skin and at 280–310 nm in 
human skin. UVA-II (320–340 nm) or UVA-I (340–400 nm) radiation can also induce the 
formation of cis-UCA % (Gibbs and Norval, 2011). It is reported that the action spectrum of 
UV induced suppression of contact hypersensitivity fits with the absorption spectrum of UCA 
but not of DNA or other components in the epidermis (Jones et al., 1996). The concentration 
of cis-UCA is elevated in UV-exposed skin in both human and mice. Cis-UCA has been 
reported to remain elevated in the serum of UV-irradiated mice. Cis-UCA concentration is 
increased in the circulation as well as in urine of UVB-irradiated individuals and this can last 
for at least two weeks. Systemically distributed cis-UCA upon photo-isomerization has been 
shown to induce systemic immune suppression (Gibbs et al., 2008). Removing the stratum 
corneum by tape stripping abrogates the UV induced suppression of contact hypersensitivity 
which suggests that UCA plays a role in UV-induced immunosuppression (Beissert and 
Schwarz, 2002).   
 
Multiple cellular targets have been suggested to be involved in cis-UCA mediated immune 




4.1.1 Cis-UCA mediated immune suppression in murine models 
Several studies have reported that UV induced cis-UCA suppresses cellular immune 
responses including contact hypersensitivity (CH) and delayed type hypersensitivity (DTH) 
(Applegate et al., 1989). This is further evidenced by murine studies showing that depleting 
the in vivo function of cis-UCA using specific Ab inhibits suppression of DTH induced by 
UV radiation (Moodycliffe et al., 1996). Ab against cis-UCA also prevents UV-induced 
photocarcinogenesis (Beissert et al., 2001). In vivo experiments have shown that cis-UCA 
induces ROS leading to DNA damage, which is suggested to trigger inhibition of DTH 
(Sreevidya et al., 2010). 
 
4.1.2 Cis-UCA mediated suppressive effect on CD4+ T cells and antigen presenting cells 
Cis-UCA down-regulates the antigen-presenting ability of mouse spleen cells by inducing IL-
10 secretion from activated CD4+ T cells (Moodycliffe et al., 1996). Langerhans cells ability 
to process and present antigen in vitro is significantly inhibited by cis-UCA, the effect of 
which can be reversed by addition of IL-12 (Beissert et al., 2001). The number of Langerhans 
cells is reduced by 62% after topical application of 20 μg of cis-UCA, which leads to 
significant suppression of mixed skin lymphocyte reaction (Norval et al., 1990).  
 
4.1.3 Cis-UCA mediated improvement of skin inflammation  
In murine models of DMSO induced-acute skin inflammation and 12-O-
tetradecanoylphorbol-13-acetate (TPA) induced-subacute skin inflammation, 2.5% and 5% 
cis-UCA suppressed inflammation and attenuated skin oedema and erythema (Laihia et al., 
2012). The clinical efficacy of cis-UCA in treating human skin conditions has also been 
investigated. 5% cis-UCA emulsion cream was well tolerated and effective in reducing trans-




patients;  eczema area severity index was improved by 5% cis-UCA in mild-to-moderate AD 
(Peltonen et al., 2014). Topical application of cis-UCA prevented the induction of 
sensitization to DNCB on human skin (Dahl et al., 2010). A clear anti-psoriatic effect was 
observed when cis-UCA was used as topical treatment for psoriatic plaques (Vestey and 
Norval, 1997) 
 
Hence, cis-UCA is a promising drug for AD but the molecular mechanisms involved in its 
action are still unclear. A number of studies have failed to demonstrate cis-UCA mediated 
immunosuppression in vitro including mitogen-induced human peripheral blood mononuclear 
cell (PBMC) proliferative responses, human mixed lymphocyte reaction (MLR) and antigen-
specific T lymphocyte responses (Gibbs, Tye et al. 2008), implying that cis-UCA may have to 
interact with other cells in a more complex fashion than can be reproduced in vitro or that the 
suppression may be mediated by other factors induced by cis-UCA in vivo. 
 
As understanding the mechanisms by which cis-UCA suppresses immune responses is 
important for AD treatments, this chapter describes experiments designed to determine the 












Chapter hypothesis and research questions 
 
Cis-UCA contributes to the clinical efficacy of NB-UVB phototherapy in AD through its 
effects on the function of regulatory T cells either directly, or indirectly through its action on 
antigen presenting cells. 
 
 Does cis-UCA induce functional regulatory T cells from human peripheral CD4+ T 
cells? 





















4.2.1 cis-UCA reduces CLA expression and CD25hiFoxp3+Treg induction from human 
peripheral CD4+ T cells. 
I first investigated the effect of cis-UCA on CD4+ T cell phenotype and particularly on the 
induction of CD25hiFox3+ Tregs. In order to determine the optimal concentration of cis-UCA 
to use, human peripheral blood CD4+ T cells were purified and cultured with plate bound 
anti-CD3 and anti-CD28 antibodies in the presence of different concentrations of cis-UCA for 
5 days as described in Chapter 2.3.1.2. The expression of CD25 and Foxp3 were analyzed by 
flow cytometry. 100 µg/ml cis-UCA has been used in murine in vitro and in vivo experiments 
(Beissert et al., 2001). Kanesaki reported that cis-UCA levels in human plasma, obtained after 
a total-body UV-B exposure of 250 J/m2 was approximately 69 µg/ml (Kanesaki et al., 1993). 
It is known that the skin concentration of UCA varies considerably between individules. 
Results showed that cis-UCA at 100 µg/ml had the strongest effect on induction of CD25hi 
Foxp3+ T cells and viability of CD4+ T cells was not affected (Fig 4.1 a & b). Thus, cis-UCA 
at 100 µg/ml was used for the following experiments.  
 
CLA interacts with E-selectin expressed on endothelial cells and directs T cell migration to 
the skin. To investigate whether cis-UCA affects T cell migration, CLA expression was 
analyzed by flow cytometry. As shown in Fig 4.1c, cis-UCA significantly decreased the 
frequency of CLA+ T cells which suggested that fewer activated CD4+ T cell could migrate 
to skin following exposure. 
 
Next cis-UCA‘s effect on Tregs was investigated. As CD127 staining was not used in this 




percentage of CD25+ cells and geometric MFI of CD25 was not affected by cis-UCA 
indicating that T cell activation was not affected. As shown in Fig 4.1f, the percentage of 
CD25hi Fopx3+ cells was significantly decreased by cis-UCA as was CLA expression on 
CD25hi Foxp3+ cells.  
 
Fig 4.1 cis-UCA modulates human peripheral CD4+ T cell phenotype. Purified peripheral CD4+ T cells 
were activated with plate bound anti CD3/28 and treated with cis-UCA for 5 days. T cell phenotype was 




treated with different concentrations of cis-UCA. b) Viability of total cells after being treated with 100 
µg/ml cis-UCA (N=14). c) Percentage of CLA+ cells of total CD4+ T cells after being treated with 
100µg/ml cis-UCA for 5 days (N=10). d-e) Percentage of CD25+ cells of total CD4+ T cells and geometric 
mean of CD25 after being treated with 100µg/ml cis-UCA for 5 days (N=14).  f) Representative FACS plot 
and the percentage of CD25hi Foxp3+ T cells after being treated with or without 100µg/ml cis-UCA for 5 
days (N=14). P value was calculated using Wilcoxon matched pairs T test. Ctrl = control cultures without 
cis-UCA  
 
4.2.2 cis-UCA modulates CD4+ T cell phenotype through 5-HT2a receptor. 
To date, little is known of how cis-UCA exerts its inhibitory effect. Systemic administration 
of serotonin receptor 2A (5-HT2aR) antagonist is reported to block cis-UCA induced immune 
suppression in a mouse model of DTH (Walterscheid et al., 2006). Therefore, I hypothesized 
that cis-UCA modulates CD4+ T cell phenotype through the 5-HT2a receptor. 
 
To assess whether human CD4+ T cells express 5-HT2aR, protein was extracted from 
purified CD4+ T cells that were either unstimulated or stimulated with plate bound anti-
CD3/28 for 5 days. The expression of 5-HT2aR was analyzed using western blot. As shown 
in Fig 4.2a, resting CD4+ T cells expressed a low level of 5-HT2aR and the expression was 
increased in activated CD4+ T cells.  
 
To further investigate whether cis-UCA modulates CD4+ T cell phenotype through 5-HT2aR, 
an agonist for 5-HT2aR was used. Due to availability of the compounds, α-methylserotonin 
(αMS) which is an agonist against all three subtypes of 5-HT2 receptor was used. CD4+ T 
cells were activated with plate bound anti-CD3/28 in the presence or absence of 1nM αMS 




cis-UCA on CD4+ T cell phenotype, as evidenced by decreasing the percentage of CLA+ 
cells and CD25hi Foxp3+ cells. (Fig 4.2b). 
 
Due to unspecificity of αMS, a specific antagonist of 5-HT2aR ketaserin (Ke) was used to 
further confirm whether 5-HT2aR mediates cis-UCA effect on CD4+ T cells. CD4+ T cells 
were activated with plate bound anti-CD3/28 and treated with 100µg/ml cis-UCA in the 
presence or absence of different concentrations of Ke for 5 days and T cell phenotype was 
analyzed by flow cytometry. As shown in Fig 4.2c, the modulatory effect of cis-UCA on the 
frequency of CD25hi Foxp3+ T cells was reversed by Ke. However, cis-UCA effect on the 
frequency of CLA+ T cells was not affected by the presence of Ke (Fig 4.2c), which indicated 
that 5-HT2aR may not be the only receptor for cis-UCA on CD4+ T cells. 
 
Murine naïve CD4+ T cells have been reported to express tryptophan hydroxylase-1 (TPH-1) 
after activation which is the rate-limiting enzyme in serotonin synthesis (Leon-Ponte et al., 
2007). To test whether purified human CD4+ T cells express TPH-1 leading to the production 
of endogenous serotonin, the expression of TPH-1 was analyzed using real-time PCR. As 
shown in Fig 4.3, there was no difference in TPH-1 expression between resting and activated 
CD4+ T cells and cis-UCA did not modulate TPH-1 expression indicating that cis-UCA did 







Fig 4.2 cis-UCA modulates CD4+ T cell phenotype through 5-HT2a receptor. Purified peripheral CD4+ 
T cells were activated with plate bound anti CD3/28 and treated with 1nM 5-HT2aR agonist α-
methylserotonin (αMS) or 100 µg/ml cis-UCA in the presence of different concentrations of 5-HT2aR 
antagonist ketaserin (Ke) for 5 days. T cell phenotype was analyzed by flow cytometry. a) Western blot of 
5-HT2aR expression on resting and activated CD4+ T cells. b) Viability, percentage of CLA+ cells and 
CD25hi Foxp3+ cells of total CD4+ T cells after being treated with 1nM αMS for 5 days (N=8).   c) 
Viability, percentage of CLA+ cells and CD25hi Foxp3+ cells of total CD4+ T cells after being treated with 
cis-UCA in the presence of different concentrations of ketaserin for 5 days (N=7). P value was calculated 





                                
Fig 4.3 Human purified CD4+ T cell TPH-1 expression is not changed on activation. Purified 
peripheral CD4+ T cells were either left unstimulated or activated with plate bound anti CD3/28 for 3 days 
in the presence or absence of 100µg/ml cis-UCA. TPH-1 expression was analyzed using real-time PCR 
(N=5). 
 
4.2.3 cis-UCA modulates CD4+ T cell function. 
4.2.3.1 Cis-UCA affects CD4+ T cell cytokine secretion.  
To further assess cis-UCA effect on CD4+ T cell cytokine secretion, a proteome profiler 
human cytokine array was performed. Cell culture supernatants from 4 donors were pooled 
together to minimize variations in individuals. Pooled culture supernatant from CD4+ T cells 
that had been activated with anti-CD3/28 for 5 days in the presence or absence of cis-UCA 
were analyzed. The result of the array is shown in Fig 4.4a. All cytokine/chemokines were 
represented in duplicate. Pixel intensity of the dots were analyzed using ImageJ software.  
Based on the semi-quantitative results, CCL4 (red boxes, Fig 4.4a) was further analyzed 
using ELISA. As shown in Fig 4.4b, cis-UCA significantly increased CCL4 secretion from 






Fig 4.4 Cis-UCA affects CD4+ T cell cytokine secretion. CD4+ T cells were activated with plate bound 
anti CD3/28 and treated with 100 µg/ml cis-UCA. Cytokine secretion was analyzed by ELISA. a) Original 
figure of proteome profiler human cytokine array. Dots representative of CCL4 have been highlighted in 
red b) Densitometry analysis of original figure of proteome profiler human cytokine array. c) CCL4 
concentration in the culture supernatant of activated CD4+ T cells being treated with or without 100 µg/ml 
cis-UCA for 5 days (N=7).  P value was calculated using Wilcoxon matched pairs T test. 
 
Previous report has shown that cis-UCA promoted the secretion of IL-10 from activated 
CD4+ T cells (Holán et al., 1998). As shown in Fig 4.5, cis-UCA significantly increased IL-
10 secretion from activated human peripheral CD4+ T cells. Although IFNγ was slightly 
increased by cis-UCA as well, it did not reach significance. The IL-10/ IFNγ ratio was also 





           
Fig 4.5 cis-UCA enhances the secretion of IL-10 from activated peripheral CD4+ T cells. Purified 
peripheral CD4+ T cells were activated with plate bound anti CD3/28 and treated with cis-UCA for 5 days. 
IL-10 (N=15) and IFNγ (N=17) concentration were analyzed using ELISA and the ratio of IL-10/ IFNγ 
(N=15) was calculated as well. P value was calculated using Wilcoxon matched pairs T test. 
 
4.2.3.2 Cis-UCA inhibits CD4+ T cell proliferation.  
Cis-UCA has been reported to inhibit the proliferation of rat bladder cancer cell line in a dose 
dependent manner (Arentsen et al., 2012).  To investigate the effect of cis-UCA on CD4+ T 
cell proliferation, purified CD4+ T cells pre-labelled with the proliferation dye ef670 were 
activated with anti-CD3/28 and treated with 100 µg/ml cis-UCA for 4 days. Proliferation of 
CD4+ T cells was analyzed by flow cytometry. As shown in Fig 4.6, cis-UCA significantly 
decreased proliferation of activated CD4+ T cells which may contribute to its ability to 




                            
Fig 4.6 cis-UCA inhibits CD4+ T cell proliferation. Pre-labelled ef670 CD4+ T cells were activated with 
plate bound anti CD3/28 and treated with 100 µg/ml cis-UCA for 4 days. Proliferation of CD4+ T cells was 
measured by flow cytometry. a) Representative FACS plot of CD4+ T cell proliferation. b) CD4+ T cell 
proliferation after being treated with 100 µg/ml cis-UCA for 4 days (N=7). P value was calculated using 
Wilcoxon matched pairs T test. 
 
4.2.3.3 cis-UCA modulates ERK signalling pathway in CD4+ T cells 
The ability of cis-UCA to affect T cell function indicates that it can trigger signaling. Cis-
UCA has been shown to trigger ERK signaling in T cell lines that are isolated from multiple 
sclerosis patients (Correale and Farez, 2013). Extracellular Signal-Regulated Kinases 1 and 2 
(ERK) and p-38 are members of the Mitogen Activated Protein Kinase (MAPK) family. 
Therefore, we set out to determine the effect of cis-UCA on ERK signaling pathways. 
Purified CD4+ T cells were first starved by culturing them in RPMI without FBS at 37 degree 
for 2h before being activated with plate bound anti CD3/28 in the presence or absence of 
100µg/ml cis-UCA alone or with 5-HT2aR antagonist. The T cell pellets were collected at 
different time points and phosphorylation of ERK was analyzed by western blot.  
 
As shown in Fig 4.7a, T cell activation led to increased phosphorylation of ERK, as expected. 




confirmed by densitometry analysis shown in Fig 4.7b. Cis-UCA's effect on ERK 
phosphorylation was reversed by 5-HT2a antagonist ketaserin (Fig 4.7 a&b) (N=3).  
 
Fig 4.7 cis-UCA modulates ERK signalling pathway in activated CD4+ T cells. Purified CD4+ T cells 
were starved for 2h before being activated with plate bound anti CD3/28 in the presence or absence of 
100µg/ml cis-UCA alone or with 5-HT2aR antagonist. The plate was spun down and T cell pellets were 
collected at different time points and proteins were extracted using RIPA buffer. Phosphorylation of ERK 
was analyzed by western blot.  a) Representative western blot image of cis-UCA and 5-HT2aR antagonist 
ketaserin effect on ERK phosphorylation. b) Densitometry analysis of cis-UCA and 5-HT2a antagonist 
ketaserin effect on ERK phosphorylation. Representative result of 3 separate experiments. 
 
4.2.3.4 cis-UCA modulates vitamin D effect on CD4+ T cells by decreasing vitamin D 
receptor (VDR) expression. 




with immune regulatory functions which has direct effects on CD4+ T cells and promotes 
differentiation and suppressive function of Foxp3+Tregs. Cis-UCA has the opposite effect of 
vitD on CD25hi Foxp3+ T cells differentiation.  To analyze whether cis-UCA can affect the 
effect of vitD on Foxp3+Tregs induction, purified human peripheral CD4+ T cells were 
activated with plate bound anti-CD3/28 and treated with either 100 µg/ml cis-UCA or 10
-7
M 
vit D or both for 5 days. As shown in Fig 4.8a, vit D alone enhanced the frequency of CD25hi 
Foxp3+ T cells as reported before, and addition of 100 µg/ml cis-UCA partially reversed this 
effect. Taken together, these results indicated that a fine balance may exist between UV-
induced anti-inflammatory molecules in terms of their ability to suppress immune responses.   
 
The biological effects of vit D are mediated by the vitamin D receptor (VDR). ERK signaling 
is suggested to be involved in VDR expression (Gocek et al., 2007). Since we have observed 
that cis-UCA partially reversed the effect of vit D on CD25hiFoxp3+ cell induction, we 
further investigated whether cis-UCA modulates vit D‘s effect by controlling its receptor. 
Purified CD4+ T cells were stimulated with plate bound anti-CD3/CD28 and treated with 
either 100 µg/ml cis-UCA or 10
-7 
M vit D or both for 3 days. The expression of VDR was 
analyzed using real-time PCR. VDR expression was increased after activation and vit D 
treatment further increased expression of VDR. However, upon stimulation, VDR expression 
in CD4+ T cells that have been treated with cis-UCA was decreased. Cis-UCA also partially 
reversed the effect of vit D on VDR expression as shown in Fig 4.8b, which suggested that 




                                     
Fig 4.8 cis-UCA modulates vitamin D effect on CD4+ T cells by decreasing VDR expression. Purified 
peripheral CD4+ T cells were activated with plate bound anti CD3/28 and treated with 100 µg/ml cis-UCA 
or 10
-7 
M vit D or both for 5 days for phenotype analysis or 3 days for VDR expression analysis. T cell 
phenotype was analyzed by flow cytometry and VDR expression was measured by real-time PCR. a) 
Percentage of CD25hi Foxp3+ cells of total cells after being treated with cis-UCA or vit D or both for 5 
days (N=5). b) VDR expression of total cells after being treated with cis-UCA or vit D or both for 3 days 
(N=5). 18s was used as house keeping gene. P value was calculated by Friedman test followed by Dunn‘s 
post-test. 
 
4.2.4 cis-UCA modulates mo-DCs phenotype. 




regulatory T cells which suggests that antigen presenting cells play an important role in the 
development of an inflammatory response. In AD patients, skin barrier defects, increased 
exposure of epidermal DCs to irritants, microbial danger signals and antigens which penetrate 
skin  can lead to the immunological changes of atopic eczema (Kubo et al., 2012). Cis-UCA's 
effect on antigen presenting cells remains elusive. To address this issue, we analyzed the 
effect of cis-UCA on human monocyte-derived DCs (mo-DCs). CD14+ monocyte were 
positively selected from PBMCs and differentiated with human GM-CSF, IL-4 for 6 days 
before being matured with LPS or PolyI/C for 24 hours or 48 hours, respectively. Phenotype 
of both immature and matured mo-DCs was analyzed by flow cytometry.  
 
As shown in Fig 4.9a, cis-UCA significantly decreased the expression of co-stimulatory 
molecules CD86 and CD40 and antigen presenting molecule HLA-DR on immature mo-DCs. 
There was a slight decrease of PD-L1 expression caused by cis-UCA on immature mo-DCs 
although it did not reach significance. The expression of co-stimulatory molecule CD80 and 
the maturation marker CD83 was not affected by cis-UCA on immature mo-DCs.  
 
In contrast, for mo-DCs matured with Poly I/C for 48h, cis-UCA did not have an effect on the 
expression of HLA-DR, CD86, CD40 and PD-L1 as shown in Fig 4.7b. Cis-UCA only 
significantly increased the expression of CD80 (Fig 4.9b). For mo-DCs matured with LPS, 
among all the surface markers measured, only the expression of PD-L1 was significantly 
decreased by cis-UCA which suggested that cis-UCA's effect on matured mo-DCs may be 




            




                      
Fig 4.9 cis-UCA modulates human mo-DCs phenotype. CD14+ monocytes were isolated from PBMCs 
and cultured with cytokines including GM-CSF and IL-4 for 6 days with or without 100µg/ml cis-UCA to 
generate immature mo-DCs. The immature mo-DCs were matured with 10ng/ml LPS or 20µg/ml Poly I/C 
for 24h or 48 h, respectively.  Phenotypes of both immature and mature mo-DCs were analyzed by flow 
cytometry. a) Expression of antigen-presenting molecule, costimulatory molecules and maturation 
molecules on immature mo-DCs.  b) Expression of antigen-presenting molecule, costimulatory molecules 
and maturation molecules on mo-DCs matured with 20µg/ml Poly I/C for 48h. c) Expression of antigen-
presenting molecule, costimulatory molecules and maturation molecules on mo-DCs matured with 10ng/ml 
LPS for 24h. P value was calculated using Wilcoxon matched pairs T test. 
 
 
4.2.5 cis-UCA promotes CD25+Foxp3+CD127-T cells induction indirectly by modulating 
mo-DCs.  




stimulatory molecules and antigen presenting molecule were decreased in immature mo-DCs. 
In order to investigate whether these immature mo-DCs were indeed less immune stimulatory, 
co-culture experiments with allogenic CD4+ T cells were performed. CD14+ monocytes were 
positively selected from PBMCs and differentiated with human GM-CSF and IL-4 for 6 days 
to generate immature mo-DCs which were matured with 10ng/ml LPS for 24h. Allogenic 
CD4+ T cells were stained with proliferation dye ef670 before being co-cultured with 
immature or matured mo-DCs. Proliferation and phenotype of allogenic CD4+ T cell were 
analyzed by flow cytometry.  
 
For allogenic CD4+ T cells that were co-cultured with immature mo-DCs differentiated in the 
presence or absence of cis-UCA, there was no difference in T cell proliferation (Fig 4.10 a). 
However, the percentage of CD25+Fopx3+CD127- cells was increased by co-culturing with 
immature mo-DCs differentiated in the presence of cis-UCA (Fig 4.10 b, N=3). The 
suppressive function of the induced CD25+Fopx3+CD127- cells was not tested in this project. 
To test this, further studies could be conducted to analyse the function of these cell by 
isolating the induced CD25+CD127- cells and co-culturing them with autologous effector T 
cells. 
 
For allogenic CD4+ T cells that were co-cultured with mature mo-DCs differentiated in the 
presence or absence of cis-UCA, there were no changes in both  parameters that were 
measured including T cell proliferation and percentage of CD25+Fopx3+CD127- cells (Fig 




      
 
 
Fig 4.10 cis-UCA promotes CD25+Foxp3+CD127-T cells induction indirectly by modulating mo-DCs. 
CD14+ monocyte were positively selected from PBMCs and differentiated with human GM-CSF, IL-4 for 
6 days to generate immature mo-DCs (i-DC) in the presence or absence of 100 µg/ml cis-UCA. i-DC were 




100µg/ml cis-UCA. Allogenic CD4+ T cells were stained with proliferation dye ef670 before being co-
cultured with immature or matured mo-DCs for 5 days. Proliferation and phenotype of allogenic CD4+ T 
cell were analyzed by flow cytometry. Representative FACS plot showing a) Proliferation b) ) percentage 
of CD25+Foxp3+CD127- cells of allogenic CD4+ T cells after being co-cultured with immature or mature 
mo-DCs that have been generated with or without cis-UCA (Gated on CD25+ cells, N=3). CD4+ T cells 
activated with plate bound anti CD3/28 was used as positive control and CD4+ T cells that were left 
unstimulated was used as negative control. Kruskall Wallis test with Dunn‘s multiple comparison post-test, 






















UVB radiation is absorbed by DNA, trans-UCA and cell membranes when it reaches the 
epidermis and upper dermis. Vitamin D production starts in skin following UV interactions 
with 7-dehydrocholesterol, which has long been thought to exert immunosuppression locally 
in skin and systemically (Schwarz et al., 2012).  However, vitamin D is not the only anti-
inflammatory molecule induced by UV irradiation and mediators other than vitamin D that 
are induced may also be involved in UV-mediated immunomodulation (Norval, 2006). UVB 
radiation causes photo-isomerization of trans-UCA to cis-UCA. Cis-UCA is reported to 
downregulate immune responses both locally and systemically. The local immuno-regulatory 
effect of cis-UCA is shown by the observation of Decara et al  that  the amount of cis-UCA 
detected in squamous cell carcinoma biopsy is 44% of total UCA which is significantly 
higher than that of healthy photo-exposed skin (Decara et al., 2008). The systemic immuno-
modulatory effect of cis-UCA was investigated in a murine colitis model. Cis-UCA 
administered subcutaneously prevented weight loss and attenuated changes in colon 
weight/length in dextran sodium sulfate induced murine colitis model (Albert et al., 2010).  
Therefore, the modulatory effect of cis-UCA on human peripheral CD4+ T cell and mo-DC 
phenotype and function was investigated.  
 
CLA interacts with E-selectin to mediate homing of CD4+ T cells to skin, which is considered 
as a biomarker for T cell mediated skin disease. CLA, as an inducible carbohydrate epitope of 
P-selectin glycoprotein ligand-1, is selectively expressed on activated T cells. Evidence 
suggests that systemic low dose UVB inhibited the migration of CD4+ T cells to skin by 50% 
during elicitation in a murine CHS model, which implies this might be one of the mechanisms 
by which UVB modulates elicitation of CHS (Rana et al., 2008). Thus, the decreased 




indicates that fewer CD4+ T cell would migrate to skin after UV radiation, which may 
contribute to the clinical observation that fewer infiltrating inflammatory cells are seen after 
UVB phototherapy. 
 
The immunoregulatory function of vitD is well recognized including its effect on Tregs. A 
previous study has shown that cis-UCA promotes CD25+Foxp3+Treg induction from human 
PBMCs (Correale and Farez, 2013). Therefore, I investigated the percentage of CD25hi 
Foxp3+ T cell after different treatments in purified CD4+ T cells. Vitamin D significantly 
increased the prevalence of CD25hi Foxp3+ T cells, which is consistent with previous studies. 
In contrast to previous study, a significant decrease of proportion of CD25hi Foxp3+ T cell 
was observed after cis-UCA treatment. The difference between whole PBMCs that were used 
in the previous study and purified CD4+ T cells used here may contribute to the different 
results we have seen since cis-UCA may affect T cell phenotype and functions indirectly via 
APCs which will be shown later.  
 
It is important to characterize the receptor(s) for cis-UCA which may provide further insights 
into the biological functions of cis-UCA, however, the receptor(s) for cis-UCA remains 
elusive. Using computational docking method, similar binding modes were observed for cis-
UA and 5-HT with 5-HT2a receptor while binding affinity for cis-UCA was relatively higher 
than 5-HT (Shen and Ji, 2009). 5-HT2aR antagonist is also reported to block cis-UCA 
induced ROS in vivo (Sreevidya et al., 2010). All these evidence suggest cis-UCA mediates 
its biological function through 5-HT2aR. In contrast, several studies suggest that 5-HT2aR is 
not the receptor for cis-UCA. For example, cis-UCA induces secretion of IL-6, TNFα and 
PGE2 from keratinocytes, which cannot be blocked by 5-HT2aR antagonist (Kaneko et al., 




HT2aR agonist DOI, which suggests cis-UCA effect is mediated by receptors other than 5-
HT2aR (Woodward et al., 2006).  
 
Here we have shown that resting purified CD4+ T cells expressed low levels of 5-HT2aR and 
that the expression of 5-HT2aR was increased after CD4+ T cells were activated by CD3/28, 
which indicated it may be the receptor for cis-UCA on CD4+ T cells. Cis-UCA effect on 
CD4+ T cell phenotype could be mimicked by 5-HT2aR agonist αMS. Due to the low 
specificity of αMS, the modulatory effect of a more specific 5-HT2aR antagonist ketaserin on 
cis-UCA effect on CD4+ T cell phenotype was investigated.  Cis-UCA effect on prevalence of 
CD25hi Foxp3+ cells could be blocked by ketaserin in a dose dependent manner, however, its 
effect on prevalence of CLA+ cells could not. These results indicate that 5-HT2a at least 
partially mediates the biological effect of cis-UCA while other receptors might also be 
involved. 
 
Many mechanisms through which cis-UCA might exercise its regulatory function have been 
proposed. Cis-UCA effect on cytokine secretion is suggested to be involved in its 
immunosuppressive function. Based on the results of cytokine array, cis-UCA effect on CCL4 
secretion was analyzed. Cis-UCA significantly increased the secretion of CCL4 from 
activated CD4+ T cells, which was suggested to be immunosuppressive. B lymphocytes 
activated by B cell receptor recruit CD4+CD25+ Tregs which inhibit the production of T cell 
mediated self-reactive antibodies by secreting CCL4 (Bystry et al., 2001). CCR5, which is the 
receptor for CCL4, is expressed on murine CD4+CD25+T cells and only on a small 
subpopulation of CD4+CD25- T cells (Wysocki et al., 2005). Previous study has shown that 
cis-UCA induces IL-10 secretion from murine naïve CD4+ T cells (Holán et al., 1998). Here, 




by cis-UCA. This result indicated that IL-10 secreting type 1 regulatory T cells may be 
induced by cis-UCA. Although there are studies showing that CD49b and the lymphocyte 
activation gene-3 are indispensable for Tr1, as mentioned in Chapter 1.2.1.2.2, it is difficult to 
define Tr1 using surface markers (Gagliani et al., 2013). Therefore, further experiments 
should be done to define the source of IL-10. Although the secretion of pro-inflammatory 
cytokine IFNγ was slightly increased by cis-UCA as well, the effect of cis-UCA on IL-10 
secretion was stronger than that on IFNγ leading to an increased IL-10/ IFNγ ratio. IL-10 
plays an important role in UV induced immunosuppression as evidenced by the loss of UV-
induced tolerance and transfer of suppression when IL-10 is neutralized by anti-IL-10 Abs. 
This result indicates that IL-10 may contribute to the systemic immunosuppressive function 
of cis-UCA. This notion is consistent with two previous studies. In vivo experiment shows 
that neutralizing cis-UCA using anti-cis-UCA mAb before UV irradiation blocks the 
production of IL-10 in spleen (Moodycliffe et al., 1996). Cis-UCA confers systemic 
immunosuppression in a murine intestinal inflammation model, the effect of which is lost in 
IL-10-/-  mouse (Albert et al., 2010). 
 
Besides cytokine secretion, cis-UCA's effect on ERK signaling has also been investigated. 
Studies have shown that ectopic activation of ERK in T cells promotes Treg generation (Li 
and Rudensky et al., 2016). Therefore, the decreased phosphorylation of ERK is in consist 
with the decreased CD25hi Foxp3+% caused by cis-UCA.  ERK signaling has been suggested 
to promote polarization of T cells toward Th2 by modulating IL-4 receptor function both in 
vivo and in vitro (Yamashita et al., 1999). Cis-UCA was shown here to decrease 
phosphorylation of ERK, which may contribute to inhibition of Th2 differentiation.   
Cis-UCA as an endogenous metabolite of histidine is reported to transport protons into the 




cis-UCA leads to decreased proliferation of several human cancer cell lines including human 
melanoma, cervical carcinoma, human bladder carcinoma and fibrosarcoma cells (Peuhu et 
al., 2010). In a murine  xenograft model of human melanoma, intratumoral injection of cis-
UCA leads to decreased proliferation of melanoma cells and increased tumor necrosis and 
caspase-3 activation (Peuhu et al., 2010). Consistent with previous studies, I have shown here 
that proliferation of purified human peripheral CD4+ T cells was significantly inhibited by 
cis-UCA. ERK signaling has been reported to promote T cell proliferation indirectly by 
modulating AP-1 activity (Chang and Karin, 2001). Therefore, the decreased phosphorylation 
of ERK signaling caused by cis-UCA that showed above may contribute to this effect. Taken 
together, these results indicate that cis-UCA may control inflammation by inhibiting T cell 
proliferation.  
 
ERK signaling is suggested to be involved in VDR expression in activated CD4+ T cells 
(Gocek et al., 2007). Based on the decreased phosphorylation of ERK and decreased 
proportion of CD25hi Foxp3+ cells in activated CD4+ T cells induced by cis-UCA showed 
above, I also tested cis-UCA effect on VDR expression. Results showed that cis-UCA 
decreased the expression of VDR in activated CD4+ T cells after three days treatment. 
Furthermore, vitamin D‘s effect on CD25hi Fopx3+ cells and VDR expression were partially 
affected by addition of cis-UCA as shown in Fig 4.8. These results suggest that cis-UCA may 
modulate the effect of vitamin D on CD4+ T cells by affecting VDR expression. 
 
Evidence suggests that the state of DC maturation could affect the development and function 
of regulatory T cells and promote T cell tolerance (Maloy and Powrie, 2001). Intravenous 
administration of cis-UCA has been shown to decrease antigen presenting ability of splenic 




cells, the effect of which is restored by systemic administration of anti-cis-UCA mAb 
(Moodycliffe et al., 1996).  Hence, we investigated the effect of cis-UCA on mo-DCs 
phenotype and function. LPS was used to activate mo-DCs not only because it is widely used 
compound for innate immune activation but also because it is an important component of 
house dust mite (HDM) which is a predominant provider of aeroallergen and a risk factor for 
AD. Besides LPS, Poly I/C was also used as another stimulus to mature mo-DCs. LPS 
interacts with Toll like receptor (TLR) 2 and 4 while Poly I/C interacts with TLR 3, which 
simulate viral infection. Cis-UCA decreased the expression of antigen presenting molecule 
HLA-DR and co-stimulatory molecules CD86 and CD40 on immature DCs while the 
expression of these molecules was not affected in matured mo-DCs, which indicates that cis-
UCA may inhibit immature mo-DCs differentiation. These results are different from previous 
study which showed that cis-UCA at 100µg/ml decreased the expression of CD86 on LPS-
matured mo-DCs (Leitch et al., 2016). As shown in Fig 4.9c, the expression of HLA-DR 
varied considerably among individules, which may contribute to the differences that showed 
here.To investigate antigen presenting function of cis-UCA treated mo-DCs, allogenic CD4+ 
T cells were co-cultured with either immature or mature mo-DCs. Early study has shown that 
in vitro treatment of splenic DC with cis-UCA does not affect its ability to stimulate 
proliferation of antigen-specific T cells (Moodycliffe et al., 1996). In the rat Trichinella 
spiralis infection model, mixed lymphocyte reaction is not modulated by subcutaneous 
injection of cis-UCA (LOVEREN, 1999). In keeping with this, there was no difference in T 
cell proliferation stimulated by either immature or mature mo-DCs cultured with or without 
cis-UCA as shown in Figure 4.10a. These results suggest that cis-UCA does not affect antigen 
presentation of immature and mature mo-DCs. Early studies have shown that spleen 
suppressor cells from UV irradiated mouse transferred to recipient mouse suppress delayed 




mAb, which indicates the involvement of cis-UCA in the generation of spleen suppressor 
cells in UV irradiated mice (Moodycliffe et al., 1996). Interestingly, the percentage of 
CD25+Foxp3+CD127- cells in allogenic CD4+ T cells was increased by co-culture with 
immature mo-DCs differentiated in the presence of cis-UCA while mature mo-DCs cultured 
with cis-UCA did not have effect on this cell population. Therefore, these data suggest that 
cis-UCA indirectly modulates Foxp3+Treg induction through antigen presenting cells.  
 
Taken together, these data suggest that cis-UCA is likely to be involved in multifaceted 
pathways reflecting its complex nature as an immunosuppressive molecule induced by UV 
irradiation. cis-UCA may exert its immuno-regulatory function by inducing production of 
immunosuppressive cytokines including IL-10 and CCL4, inhibiting phosphorylation of ERK, 
inhibiting CD4+ T cell proliferation and inhibiting the expression of co-stimulatory molecules 
on immature mo-DCs leading to generation of T cells with a T regulatory phenotype while it 
















 Cis-UCA may prevent excess activated T cells infiltrating the skin by decreasing the 
prevalence of CLA+ cells. 
 1,25(OH)2D and cis-UCA differentially affect CD25hi Foxp3+cell induction and the 
ratio of 1,25 (OH)2D and cis-UCA may determine the outcome of activated CD4+ T 
cells 
 Cis-UCA modulates CD4+ T cell phenotype via 5-HT2aR. 
 Cis-UCA modulates inflammatory responses by inhibiting CD4+ T cell proliferation, 
phosphorylation of ERK signaling and inducing the production of immunosuppressive 
cytokines including IL-10 and CCL4. 
 Cis-UCA modulates 1,25 (OH)2D effect on CD4+ T cell through VDR. 

















Chapter 5 Investigating the role of FLG genotype and biomarkers reflecting immune 
polarization in clinical efficacy of NB-UVB phototherapy 
 
5.1 Introduction 
Within the last two decades, NB-UVB phototherapy with wavelengths of 311 nm of UV 
irradiation has turned out to be a major therapeutic strategy for a variety of skin diseases, 
including psoriasis, mycosis fungoides, polymorphic light eruption and AD. In comparison 
with psoriasis, which is still the most frequent indication for NB-UVB phototherapy, a 
reasonable number of AD patients do not respond to the treatment or even get worse after 
phototherapy. In general, AD patients respond less reliably to phototherapy. The majority of 
studies investigating NB-UVB phototherapy focus on clinical responses while few of them 
have evaluated the mechanisms of NB-UVB phototherapy in patients with AD. There are only 
limited data on the molecular effects of UV radiation in patients with AD. The lack of 
mechanistic studies in therapeutic trials in patients with AD is partially due to the incomplete 
understanding of the pathogenic mechanisms contributing to the disease (Tintle et al., 2011). 
 
It is thus important to identify characteristics of AD patients that will determine whether they 
will respond to phototherapy. Hence, characteristics such as genotype, biomarkers reflecting 
immune polarization and clinical phenotype could be used in clinical study design and drug 
development to select existing or novel therapies to patients most likely to benefit from a 
mechanism-based treatment. 
 
It is well known that UV irradiation induces production of vitamin D which is suggested to be 
responsible for UV induced immunosuppression that contributes to clinical effect of NB-




the production of anti-microbial peptide β-defensin 1 and 2 in keratinocytes which contributes 
to the enhanced expression of these anti-microbial peptides in patients with AD treated with 
NB-UVB phototherapy (Gambichler et al., 2006). 
 
However, UV radiation can suppress contact hypersensitivity responses and allergic airway 
disease in vitamin D3-deficient mice indicating the immune functions may be controlled by 
vitamin D3-independent mechanisms (Gorman et al., 2012). Further studies have shown that 
UV radiation induces a similar extent of immunosuppression in mice which do not express 
vitamin D receptor (VDR) (Schwarz et al., 2012). Other studies showed that changes in 
vitamin D produced in skin by UV irradiation have not been correlated with local immune 
regulation (Hart et al., 2011) 
 
Vitamin D is not the only anti-inflammatory molecule induced by UV irradiation. For 
example, UVR-induced prostaglandin E2 (PGE2) mediates systemic immunosuppression by 
reducing the ability of progenitor dendritic cells from the bone marrow to develop into 
effective antigen-presenting cells (Ng et al., 2010). Therefore, UV radiation induced 
mediators other than vitamin D may also be involved in immunomodulation (Norval, 2006). 
 
As introduced in Chapter 1.4.1.4.2, NO is released from human skin upon exposure to UV 
irradiation. NO released by this process has been shown to have systemic modulatory effect. 
For example, Liu et al show that UVA irradiation induces NO production from human skin 
which leads to vasodilation of arterial vasculature and decrease of blood pressure (Liu et al., 
2014). cis-UCA formation is also induced by UV irradiation (see Chapter 1.4.1.4.3). Cis-UCA 
may also have systemic effects as evidenced by systemic administration of an antagonist 




(Walterscheid et al., 2006). cis-UCA is a breakdown product of filaggrin, therefore, FLG 
genotype can be used as an indication of cutaneous cis-UCA concentration. The FLG 
mutations tested in this project include R501X and 2282del4, both of which stop protein 
translation within the first filaggrin repeat. Homozygous for these two mutations leads to 
pronounced AD phenotype (Weidinger et al., 2006). I have shown in Chapter 3 that NO 
directly induces functional Foxp3+Tregs with enhanced skin migration ability and in Chapter 
4 that cis-UCA promotes Foxp3+Tregs differentiation indirectly by modulating human mo-
DCs while decreasing CD4+ T cell proliferation and the percentage of potentially skin-
homing CLA+ cells, therefore likely downregulates systemic inflammation. 
 
Chapter hypothesis: 
Based on these results, I hypothesize that besides vitamin D, NO and cis-UCA may contribute 
to the clinical efficacy of NB-UVB phototherapy for AD patients through their effects on T 
cells.  
I tested this hypothesis by asking the following questions:- 
 Does serum concentration of vitamin D or nitrate or FLG genotype correlate with 
clinical efficacy of NB-UVB phototherapy? 
 











5.2.1 Patients recruitment 
The study was approved by the National Research Ethics Service (NRES) Committee North 
West – Preston (14/NW/1409). Patients were recruited from Department of Dermatology at 
University of Edinburgh. They were provided with a patient information sheet which explains 
the study in layman‘s terms and were given at least 24 hours to consider whether to 
participate the study. Then they signed a consent form before the start of study.  
 
For inclusion in the study, patients had to have a clinical diagnosis of AD, be between the 
ages of 16 and 80 years and on the waiting list for UVB phototherapy. 
 
The exclusion criteria were: 
1. Treatment with systemic corticosteroids or other immune response modifying 
systemic drugs such azathioprine or methotrexate in four weeks before the study starts.  
2. Taking aspirin or other NSAIDs in the week before each blood sampling. 
3. Inability to give informed consent. 
4. Pregnancy 
5. Skin type 1 (always burns, never tans) 
6. involved in current research or have recently been involved in any research prior to 
recruitment 
 
In total, 11 male AD patients and 8 female AD patients were recruited, aged between 23~56. 
The severity of the AD was measured by SCORAD (SCORing Atopic Dermatitis) at the start 
and after eight weeks treatment. This is a composite measure of the area and intensity of AD 




the patient.  Blood samples were taken before and after an 8 week treatment. Plasma 
concentration of 25(OH) vitamin D and nitrate which is one of the end products of NO were 
analysed for all the recruited patients. FLG genotype was analysed by the Wellcome Trust 
Clinical Research Facility. The detailed method was described in 2.3.9. Whole blood staining 
for immune cell subset was performed for blood samples taken from these patients. Table 5.1 
showed the patients information. Within the 19 patients recruited, 3 of them were FLG –null 
mutation carriers.  
 
Table 5.1 Patients information.  
 
As shown in Fig 5.1a, SCORAD, which was used in this study as an indication for AD 
severity, decreased in all patients after 8 weeks NB-UVB phototherapy.  Under the ethics for 
this study, NB-UVB phototherapy was only given to patients who had phototherapy before 
and responded to the treatment or to those whose disease was self-reported to get better on 




study getting better after 8 week treatment. However, there was still some variation in the 
patients‘ responses to phototherapy. As shown in Fig 5.1b, although those with FLG-null 
mutations showed good improvement, there was no significant difference between AD 
patients with WT FLG compared to those with FLG-null mutations, which suggested that 
FLG genotype could not be used as a biomarker to predict the clinical efficacy of NB-UVB 
phototherapy. Besides FLG mutations, copy number variation with filaggrin also contributes 
to the risk of AD (Elias and Schmuth., 2009). Considerting the small number of AD patients 
with FLG mutations recruited, this would need to be repeated on a larger number to make any 
definite conclusion. 
                           
Fig 5.1 FLG genotype could not be used as a biomarker to predict the clinical efficacy of NB-UVB 
phototherapy. a) Severity of AD before and after 8 weeks NB-UVB phototherapy. b) Disease 
improvement in patients with wild type FLG and in patients with FLG null mutations. N=19  P value was 
calculated using Wilcoxon matched pairs T test. 
 
5.2.2 Plasma 25(OH) vitamin D concentration was increased after 8week of NB-UVB 
phototherapy and changes of plasma concentration of 25 (OH) vitamin D did not 
correlate with disease improvement after NB-UVB phototherapy. 
 Plasma concentration of 25(OH) vitamin D was analysed by ELISA. As shown in Fig 5.2a, 




phototherapy. The correlation between changes of plasma concentration of 25(OH) vitamin D 
and disease improvement after NB-UVB phototherapy was analysed. As shown in Fig 5.2b, 
changes of plasma concentration of 25(OH) vitamin D did not correlate with disease 
improvement. These results suggested that vitamin D was not responsible for all the 
beneficial effect induced by phototherapy.  
 
                       
Fig 5.2 Plasma 25(OH) vitamin D levels was increased after NB-UVB phototherapy and changes of 
plasma concentration of 25(OH) vitamin D did not correlate with disease improvement.  a) Plasma 
25(OH) vitamin D concentration before and after treatment. b) Correlation between changes of 25(OH) 
vitamin D concentration and disease improvement. P values were calculated using the non-parametric 
Wilcoxon matched pairs test (Fig 5.2a) and Spearman rank correlation (Fig 5.2b). N=19. 
 
5.2.3 Plasma nitrate concentration was not affected after 8 week of NB-UVB 
phototherapy and changes of plasma concentration of nitrate did not correlate with 
disease improvement after NB-UVB phototherapy.  
Plasma nitrate concentration was analysed using Nitric Oxide (total) Assay Kit from Thermo 
Fisher (Fountain Drive, Renfrew, UK). As shown in Fig 5.3b, changes of plasma 
concentration of nitrate did not show any significant difference between before and after 





                   
 Fig 5.3 Plasma nitrate concentration was not affected after 8 week of NB-UVB phototherapy and 
changes of plasma concentration of nitrate did not correlate with disease improvement. a) Nitrate 
concentration before and after treatment. b) Correlation between changes of nitrate concentration and 
disease improvement. P values were calculated using the non-parametric Wilcoxon matched pairs test (Fig 
5.3a) and Spearman rank correlation (Fig 5.3b). N=19. 
 
5.2.4 Circulating CD4+CD25+CD127low/- Tregs and CLA+Tregs were not affected after 
NB-UVB phototherapy and the change of these two cell populations did not correlate 
with disease improvement. 
To investigate whether UVB phototherapy affected the levels of circulating 
CD4+CD25+CD127low/- Tregs and especially of CLA+Tregs, and whether the changes of 
these subsets correlated with clinical efficacy of NB-UVB phototherapy, the percentage of 
these two cell populations in the whole blood were analysed by flow cytometry. As shown in 
Fig 5.4a, although half of the patients show an increase in Tregs after NB-UVB, this was not 
significant as such an increase was not observed for other patients. The change of 
CD4+CD25+CD127low/- Tregs did not correlate with disease improvement after 8 weeks of 




treatment and the changes of CLA+Tregs did not correlate with disease improvement either.  
                  
Fig 5.4 Circulating CD4+CD25+CD127low/- Tregs and CLA+Tregs were not affected after NB-UVB 
phototherapy and the change of these two cell populations did not correlate with disease 
improvement. After removing plasma, blood was diluted twice with ice cold PBS and stained with 
viability dye ef780. After viability staining, percentage of CD4+CD25+CD127low/- Tregs and CLA+Tregs 
were analysed using flow cytometry. a) Percentage of CD4+CD25+CD127low/- Tregs in whole blood.  b) 
Correlation between changes of CD4+CD25+CD127low/- Tregs and disease improvement after NB-UVB 
phototherapy. c) Percentage of CLA+ CD4+CD25+CD127low/- Tregs in whole blood. d) Correlation 
between changes of CLA+CD4+CD25+CD127low/- Tregs and disease improvement after NB-UVB 
phototherapy. P value was calculated by Spearman rank correlation (N=19). 
 
Besides regulatory T cells, other markers related with immune responses were analysed on 
total CD4+ T cells. Two of these markers were affected by NB-UVB phototherapy. As shown 
in Fig 5.5a, expression of the activation marker CD69 on CD4+ T cells was decreased after 




(Fig 5.5b). Taken together, these results indicated that markers related with CD4+ T cell 
activation and migration to the skin were decreased by NB-UVB phototherapy and the 
importance of these changes in determining clinical efficacy of NB-UVB phototherapy 
required further investigation. 
                          
Fig 5.5 Markers reflecting CD4+ T cell activation and migration were decreased after NB-UVB 
phototherapy. After removing plasma, blood was diluted twice with ice cold PBS and stained with 
viability dye ef780. After viability staining, markers related with immune responses were stained and 
analysed using flow cytometry. a) Geometric mean of CD69 expression on CD4+ T cells in whole blood. b) 
Geometric mean of CLA expression on CD4+ T cells in whole blood. P value was calculated by a non 














Previous studies have shown that patients with AD respond differently to phototherapy. It has 
been shown that among 15 patients with AD treated with NB-UVB phototherapy, 66% 
improved and duration of therapy varied between 3 to 30 months. In Edinburgh, patients with 
AD were asked whether they tended to get better on exposure to sunlight, or with previous 
phototherapy before being selected for treatment with phototherapy.  This selection bias may 
account for the fact that all patients recruited in this study improved after NB-UVB 
phototherapy.  The second weakness of the current study was the UV dose that AD patients 
received was adjusted based on their biological responses during phototherapy since this was 
an observational study. Therefore, although patients had been through 8 week treatment, the 
total UV dose they received was different, which may contribute to the different immune 
responses in AD patients.  
 
Here, I have shown that FLG genotype cannot be used as biomarker to predict clinical 
efficacy of NB-UVB phototherapy and changes in concentration of plasma 25 (OH) vitamin 
D and nitrate did not correlate with disease improvement. The number of recruited patients 
with FLG mutations in this study was low. Of 19 patients, only 3 carried FLG mutations. 
These 3 patients showed varied responses to phototherapy which suggested that FLG 
mutations did not affect patients‘ responses to NB-UVB phototherapy. An extension of the 
study with larger numbers of participants would be needed to confirm these results. Studies 
have shown that filaggrin expression negatively correlates with mast cell tryptase number in 
the nonlesional granular layer of AD patients (Ilves et al., 2015). It is also suggested that 
filaggrin deficiency associates with a defective antimicrobial barrier and increased 
colonization of Staphylococcus aureus which will further inhibits terminal differentiation of 





Plasma vitamin D concentration was significantly increased after NB-UVB phototherapy 
although the changes in concentration of this molecule did not correlate with disease 
improvement which was consist with previous studies and further indicated that vitamin D 
was not responsible for all the clinical beneficial effect of NB-UVB phototherapy (Hart et al., 
2011). Plasma concentration of nitrate was not affected after NB-UVB phototherapy. The 
change of nitrate concentration did not correlate with disease improvement either. One of the 
confounding factors for plasma nitrate concentration was diet. Nitrate is both a storage form 
for nitric oxide and an end product of its oxidation (Mowbray et al., 2009).  The major source 
of nitrate in the circulation is from diet which it is not possible to control for in this pragmatic 
observational study.  Overall levels of nitrate in the circulation might thus be an indicator for 
expected NO levels following UV radiation, but it is difficult to quantify overall NO activity 
from serum nitrate levels alone.  Another possibility is NO reacts with environment and exerts 
its action locally. In humans, the concentration of nitrite and RSNO are 25 and 360 times 
higher in skin than in plasma. Adnana N. Paunel et al showed that upon exposure to UVA, 
nitrite and RSNO were photolysed to generate NO, the concentration of which was 
comparable or even higher than that produced by cytokine activated human keratinocyte 
cultured with maximal iNOS activity in vitro. NO rapidly diffuses and penetrates cell 
membranes with a diffusion distance of 500 µm in tissue (Paunel et al., 2005). In the context 
of the in vitro results described in Chapter 3 showing that NO directly promoted generation of 
Foxp3+ Tregs, local generation of NO may promote Foxp3+Tregs within the skin. To test this, 
further studies could be conducted by analysing the correlation between cutaneous 
concentration of nitrate and presence of Foxp3+Tregs in the skin. To detect the cutaneous 
concentration of NO, samples such as fluid from suction blister should be used. The third 




Nitric Oxide Assay Kit which contains Griess Reagent can only detect nitrite and nitrate 
which leads to the underestimated concentration of UV-induced NO. 
 
Tregs are important in the resolution of allergic immunity. As summarized in Chapter 1.3.5, 
reports about the number and function of Tregs in patients with AD remain controversial.  In 
this study, the percentage of CD4+CD25+CD127low/- Tregs and CLA+ Tregs in whole blood 
were not significantly altered after treatment. This is consistent with previous studies showing 
that Foxp3+ Tregs in patients with AD were not modulated by NB-UVB phototherapy 
(Majoie et al., 2009). I have shown that the three UV irradiation induced molecules vitamin D, 
nitric oxide and cis-UCA all led to the generation of Foxp3+Tregs from CD4+ T cells either 
directly or indirectly as described in Chapter 3 and 4, however, the change in the proportion 
of CD4+CD25+CD127low/- Tregs in blood did not correlate with the change of SCORAD 
after treatment indicating that in vivo modulation of Tregs was complicated and interfering 
with anti-inflammatory molecules alone may not be enough to promote the generation of 
Tregs systemically. Tregs migration might contribute to this result as well since I have shown 
that CD4+ T cells migration was affected by UV-induced NO and cis-UCA leading to no 
drastic changes of Tregs was observed in the blood. These results also confirm that it is 
important to investigate the presence of Foxp3+Tregs in the skin before and after NB-UVB 
phototherapy to see whether it is correlated with patients‘ response to phototherapy.  The 
small number of Tregs circulating in blood meant that the function of Tregs before versus 
after treatment could not be tested in this study which may be important for evaluation of the 
clinical efficacy of NB-UVB phototherapy.  
 
Tissue-selective trafficking of T lymphocytes is mediated by a complex interplay between 




number of T cells infiltrating the skin is correlated with disease activity (Schön et al., 2003). 
Therefore, prevention of T cells migration to skin appears to be an attractive target to treat 
inflammatory skin diseases. Here, I have shown that the expression of CLA on CD4+ T cells 
was decreased after treatment, which suggested that skin migration of CD4+ T cells was 
modulated by NB-UVB phototherapy. However, a previous study has shown that blocking E-
selectin using specific antibody did not improve psoriasis in a clinical trial (Bhushan, Bleiker 
et al. 2002). This suggests that although CLA is important in T cell migration, interfering with 
a single selectin alone may not be enough to prevent the inflammatory responses in AD. 
Therefore, further studies investigating chemokines and other adhesion molecules such as 





















 All donors improved after NB-UVB therapy 
 
 Concentration of circulating 25 (OH) vitamin D, but not of nitrate, was increased after 
NB-UVB therapy. 
 
 FLG genotype cannot be used as biomarkers to predict AD patients‘ responses to NB-
UVB phototherapy. 
 
 Changes in the concentration of 25(OH) vitamin D and nitrate did not correlate with 
disease improvement after NB-UVB phototherapy. 
 















Chapter 6 General Discussion 
6.1 Factors determining AD patient response to UV-B therapy. 
Although it is commonly referred to as a single disease, recent studies suggest that AD can be 
categorized into different subtypes based on disease onset, immune polarization and gene 
variant (Leung and Guttman-Yassky 2014). Studies have shown that different clinical 
phenotypes of AD are associated with distinct activation or suppression pattern of immune 
responses. For example, there are distinct differences in cytokine production in patients with 
intrinsic versus extrinsic AD, which indicates that these patients may respond differently to 
the same treatment (Suárez-Farinas, Dhingra et al. 2013). 
 
Within the last two decades, NB-UVB therapy with wavelengths of 311 nm has turned out to 
be a major therapeutic strategy for a variety of skin diseases. In the clinical study conducted 
in my thesis, all patients improved after 8 weeks of treatment due to the pre-selection of 
patients undergoing NB-UVB phototherapy in the Dermatology department in Edinburgh. 
Still the patients exhibited different extent of responses for NB-UVB phototherapy in AD 
which is consistent with previous studies (Mok, Koh et al. 2014).   
 
Although NB-UVB phototherapy has been recognized for its good safety profile regarding 
acute adverse events, concerns remain regarding long term use.  Risk of developing skin 
cancer after NB-UVB phototherapy is not the main issue, as evidenced by Osmancevic et al 
who investigated the risk of skin cancer in 160 psoriasis patients who had been treated with 
UVB for more than 100 times during the past 5 years and showed that the risk for developing 
skin cancer in UVB-treated patients is similar to the general population (Osmancevic, 
Gillstedt et al. 2014). Similar results have been published for children aged 16 or under (Sen, 




phototherapy department every time and doctors with special training are required. Some 
patients cannot endure the associated heat and sweating and others have photosensitivity or 
co-existing polymorphous light eruption (Walling HW et al., 2010). Therefore, it is would be 
helpful to be able to identify those patients who will not respond to the treatment to avoid 
these issues for patients who are less responsive to NB-UVB phototherapy. 
 
Therefore, I set out to determine the factors that contribute to the clinical efficacy of NB-
UVB phototherapy.  
 
6.1.1 FLG Genotype 
Gene variants are reported to affect clinical efficacy of NB-UVB phototherapy.  It is 
suggested by Dai et al that single-nucleotide polymorphisms in genes related with nucleotide 
excision repair pathways that contribute to repair DNA photoproducts are associated with the 
efficacy of NB-UVB therapy in Chinese patients with active vitiligo (Dai, Zhou et al. 2015). 
 
Within the study performed during my thesis, 19 AD patients were recruited and only 3 of 
them were FLG null mutation carriers. These 3 patients showed medium responsiveness to 
the treatment which indicates that FLG mutations do not affect clinical efficacy of NB-UVB 
phototherapy.  One confounding factor for this study was the UV dose AD patients received. 
Although they were all treated with NB-UVB phototherapy for 8 weeks, the total dose of UV 
irradiation they received was different, as adjusted according to their biological responses. 
Further studies comparing AD patients with and without FLG null mutations receiving same 
dose of NB-UVB irradiation are necessary to determine the effect of FLG mutations on the 





Although FLG null mutations in this study did not correlate with clinical efficacy of NB-UVB 
phototherapy, FLG status may still provide useful information in determining the best 
treatment for AD patients. FLG null mutations result in barrier defects and enhanced allergen 
penetration as summarized in the Introduction 1.1.3.2. Decreased suppressive function of 
Tregs and increased resistance of effector T cells to the modulation of Tregs both contribute 
to the loss of immune suppression seen in the presence of strong stimulation (Baecher-Allan 
et al. 2001). Studies have shown that repetitive stimulation of Tregs through TCR/CD28 
rendered them less suppressive and more inflammatory by secreting IL-17 (Beriou et al. 
2009). More importantly, the migratory behaviour of these Tregs was also affected leading to 
accumulation of the non-functional Tregs in the skin (Rappl, Schmidt et al. 2008). Therefore, 
skin barrier improving therapy may contribute to the resolution of AD through several 
mechanisms including prevention of allergen penetration and enhancing Tregs function. 
Taken together, the combination of skin barrier improving therapy and NB-UVB 
phototherapy may be more effective. 
 
6.1.2 Factors reflecting immune responses 
Distinct immune-polarized pathways exist in various AD subsets, which may affect the 
clinical efficacy of treatment. For example, significantly enhanced expression of IL-17, IL-22 
and IL-23 have been reported in intrinsic AD patients with normal IgE level, which suggested 
that these patients were potentially more responsive to suppression of the IL-17/IL-23/IL-22 
polarized immune axes. Therefore, IgE concentration can be used to determine the effective 
treatment for AD (Leung and Guttman-Yassky 2014). This evidence suggests that 
development of biomarkers to assess the immune polarization in AD may offer valuable 





Here, I have shown that systemic 25 (OH) vitamin D concentration was significantly 
increased after NB-UVB phototherapy, as previously reported. However, the change in 25 
(OH) vitamin D did not correlate with disease improvement, which confirmed my original 
hypothesis that vitamin D was not responsible for all the clinical beneficial effect of NB-UVB 
phototherapy. Systemic nitrate concentration was analysed as well. Nitrate concentration was 
not affected after treatment and the change of systemic nitrate did not correlate with disease 
improvement either. Taken together, these results suggested that systemic 25 (OH) vitamin D 
and nitrate could not be used as a biomarker to predict clinical efficacy of NB-UVB 
phototherapy. 
 
6.2 NB-UVB phototherapy in AD: systemic effect vs local effect 
The exact mechanism of NB-UVB therapeutic action remains poorly understood and it is not 
clear whether local or systemic effect is more important. It is suggested that NB-UVB 
phototherapy improves psoriasis through local effects (Dawe, Cameron et al. 2002). Ekman et 
al reported that although NB-UVB therapy improves skin symptoms, it did not affect 
chemokine level in serum from psoriasis vulgaris patients. Chemokine production of PBMC 
activated with either LPS or anti CD3/28 was not affected by NB-UVB therapy either, leading 
to the conclusion that the effect of NB-UVB may be more focused on local inflammation than 
on systemic  (Ekman, Sigurdardottir et al. 2013).  
Here I showed that the expression of markers reflecting T cell activation CD69 on CD4+ T 
cells in blood was decreased (p=0.09) after NB-UVB phototherapy in AD, which suggested a 
systemic inhibition of CD4+ T cell activation after treatment. The expression of CLA, a 
marker related to CD4+ T cell migration, was also down-regulated (p=0.064) after NB-UVB 




inflammatory skin disease is characterized by the accumulation of lymphocytes in skin. The 
recruitment of lymphocytes is suggested to be mediated by the combined actions of 
chemokines and interaction between lymphocytes and endothelial cells mediated by cell 
adhesion molecules (Leung, Boguniewicz et al. 2004). Therefore, the decreased systemic 
CD4+ T cell activation and skin migration may contribute to the clinical beneficial effect of 
NB-UVB phototherapy. This is consistent with a previous study reported by Yule et al that 
NB-UVB phototherapy improved AD through both local and systemic effects and a variation 
in which response dominated existed between patients (Yule, Dawe et al. 2005). Taken 
together, these results indicate that NB-UVB phototherapy improves AD at least partially 
through systemic effect.  
 
6.3 Regulatory T cells 
It is well known that UV irradiation induces the production of vitamin D, which is suggested 
to be responsible for the immunosuppressive effect of UV irradiation. However, UV 
irradiation has been shown to suppress murine model of multiple sclerosis independently of 
vitamin D production (Becklund, Severson et al. 2010). Other studies showed that changes in 
vitamin D production in skin by UV irradiation have not been correlated with local immune 
regulation (Hart, Gorman et al. 2011). Taken together, these results suggest that vitamin D has 
similar immunosuppressive function as UV irradiation but does not account for all the effects 
of UV induced immunosuppression.  
 
Therefore, I studied the in vitro effect of two UV-induced anti-inflammatory molecules NO 
and cis-UCA on human peripheral CD4+ T cells and mo-DCs phenotype and function. 




Chapter 1.2. So I focused on the effect of these two molecules on Tregs differentiation and 
function. 
 
As shown in Chapter 3, NO did not affect the phenotype of human mo-DCs and exerted its 
effect on human peripheral CD4+ T cells directly. NO increased the proportion of 
CD25+Foxp3+CD127- T cells from total CD4+ T with enhanced expression of CLA 
indicating their ability to migrate to the skin. The MFI of Foxp3 on the induced cell 
population was also increased by NO which indicated their enhanced suppressive effect. The 
effects of NO on CD4+ T cells were mediated by cGMP. The increased proportion of 
CD25+Foxp3+CD127- T cells was not due to lesser proliferation of other T cell populations 
such as the Foxp3- T cells since NO inhibited the proliferation of both cell populations to a 
similar extent. I did not test the final number of Foxp3+ cells after culture, therefore, one 
possibility I cannot rule out was NO selectively killed Foxp3- T cell population leading to the 
increased proportion of Foxp3+ cells. But the results that NO also enhanced the proportion of 
CD25+Foxp3+CD127- T cells from CD4+CD25- cells further confirmed that NO could 
induce the generation of CD25+Foxp3+CD127- Treg cells. Besides, the ratio of effector T 
cells and Tregs is more important than the actual number of Foxp3+Tregs in determining the 
outcome of an immune response in humans, therefore, the increased proportion of 
CD25+Foxp3+CD127-cell may be of more clinical relevance.  
 
In contrast to mouse CD4+ T cells, TGF-β or activation induced Foxp3 expression in human 
CD4+ T cells does not confer suppressive function of Tregs (Tran, Ramsey et al. 2007). 
Therefore, the suppressive function of NO-induced CD25+Foxp3+CD127-cells was further 
analysed. Results showed that NO-induced Foxp3+ Tregs were functional as evidenced by 




induced Foxp3+Tregs were mediated by membrane bound TGF-β and PD-1/PD-L1 but not 
CTLA-4. The cytokines IL-10 secreted by NO-treated CD4+ T cells was not sufficient for the 
suppressive function of NO-induced Fopx3+Tregs.  
 
The phenotype of UV-induced Tregs has been summarized in Chapter 1.4.1.3. UV-induced 
Tregs express functional CTLA-4 and secrete high levels of IL-10 and TGF-β. It is suggested 
that the immunosuppressive function of UV-induced Tregs is partially mediated by CTLA-4. 
In a murine contact hypersensitivity model, transferring UV-induced Tregs renders recipient 
mice unresponsive, the effect of which is lost by injecting anti CTLA-4 Ab (Schwarz, Beissert 
et al. 2000). Taken together, this suggests that NO-induced Fopx3+Tregs are not equivalent to 
UV-induced Tregs and UV irradiation might induce the generation of Foxp3+Tregs through 
multiple mechanisms. Alternatively, this could also be due to intrinsic differences between 
mice and humans.  
 
In order to investigate the correlation between nitrate and Tregs in vivo, the percentage of 
Tregs in AD patients‘ blood before and after NB-UVB phototherapy was investigated. 
However, the percentage of Tregs was not consistently increased in AD patients after 8 week 
treatment. There might be two possible reasons for this. Firstly, previous studies have shown 
that local proliferation of Tregs can happen within the skin. It is reported by Clark that natural 
Tregs and their precursors existed in human skin and could be expanded by dermal fibroblasts 
in combination with IL-15 (Clark and Kupper 2007).  As summarized in Chapter 3.1, the 
concentration of nitrogen species, which will release NO upon exposure to UV irradiation, is much 
higher in skin than in plasma. Therefore, it is possible that systemic concentration for NO is not high 
enough to generate Foxp3+Tregs and NO induced Foxp3+Tregs happen locally in skin. Secondly, it 




Considering that NO-induced Foxp3+ Tregs have higher expression of CLA, it is possible that these 
Foxp3+Tregs already migrated to skin and cannot be detected in blood.  The importance of 
Foxp3+Tregs in AD have been reported in previous studies showing that despite the presence of IL-
10 secreting Tr1, the dys-regulated disease causing effector T cells was still observed in AD lesions 
with impaired CD4+CD25+FoxP3+ T-cell infiltration (Verhagen, Akdis et al. 2006).  
 
In Chapter 4, the effect of cis-UCA on human peripheral CD4+ T cells was analysed.  Cis-
UCA exerted both anti-inflammatory and pro-inflammatory effect on CD4+ T cells. Cis-UCA 
may contribute to suppression of skin inflammation by decreasing the proportion of CLA+ T 
cells of total CD4+ T cells that have been activated with plate-bound anti-CD3/28 for 5 days. 
Cis-UCA also inhibited inflammation by decreasing CD4+ T cell proliferation, 
phosphorylation of ERK signalling and increasing secretion of anti-inflammatory cytokines 
IL-10 and CCL4 which will contribute to the recruitment of Tregs. On the other hand, cis-
UCA may promote inflammation by decreasing the proportion of CD25hi Fopx3+ cells and 
affecting vitamin D‘s effect via decreasing VDR expression, which suggested that there might 
be a fine balance between UV-induced anti-inflammatory molecules.  
 
Besides its direct effect on peripheral CD4+ T cells, cis-UCA may affect CD4+ T cell 
phenotype and function indirectly through antigen presenting cells. Therefore, the effect of 
cis-UCA on human mo-DCs was also investigated. Results showed that cis-UCA decreased 
the expression of antigen presenting molecules HLA-DR and co-stimulatory molecules CD86 
and CD40 on immature mo-DCs. The immune stimulatory effect of cis-UCA treated 
immature mo-DCs was analysed by co-culturing with allogenic CD4+ T cells. Results 
showed that cis-UCA treated immature mo-DCs were indeed less immune stimulatory as 




allogenic CD4+ T cells. Study has shown that the threshold of antigen to active Foxp3+ Tregs 
is estimated to be 10-100 times lower than that is needed to activate naïve T cells (Sakaguchi, 
Yamaguchi et al. 2008). This implies that DCs with low expression levels of CD80/CD86 
preferably activate Tregs than naïve T cells. However, the expression of antigen presenting 
molecules and co-stimulatory molecules on LPS-matured mo-DCs were not affected by cis-
UCA and cis-UCA treated LPS-mature mo-DCs did not affect the proliferation and the 
proportion of CD25+Foxp3+CD127- cells when co-cultured with allogenic CD4+ T cells. 
Considering LCs as the major antigen presenting cells in the epidermis where the 
concentration for cis-UCA is relatively high are mainly immature antigen presenting cells, 
these results suggest that cis-UCA‘s effect on antigen presenting cells is more important in 
maintaining the homeostasis of skin by keeping immature DCs even less immune stimulatory 




Vitamin D is not the only anti-inflammatory molecule induced by UV irradiation and is not 
responsible for all the beneficial effects of NB-UVB phototherapy in treating patients with AD. UV 
irradiation also photolyses nitrogen-species to release NO and converts trans-UCA to immune 
suppressive cis-UCA in the skin. This study described a novel function of NO to directly induce 
functional Foxp3+Tregs with enhanced skin migration ability which mediate their suppressive 
function through membrane bound TGF β and PD-1/PD-L1 but not CTLA-4.  Cis-UCA has both 
anti- and pro-inflammatory effect on human peripheral CD4+ T cells. Cis-UCA suppressed 
inflammation through decreasing the percentage of CLA+ cells, inhibiting CD4+ T cell proliferation, 
inhibiting ERK phosphorylation and increasing IL-10 and CCL4 secretion while it might promote 




which may affect the immune suppressive function of vitamin D.  cis-UCA also affects human mo-
DCs phenotype by decreasing the expression of HLA-DR and co-stimulatory molecules CD86 and 
CD40 rendering these cells less immune stimulatory as evidenced by enhanced generation of 
CD25+Foxp3+CD127- cells when co-cultured with allogenic CD4+ T cells.  
 
The clinical study first investigated the mechanisms responsible for the clinical efficacy of this 
treatment, and I have shown that expression of CLA and CD69 on CD4+ T cells was decreased after 
8 week NB-UVB phototherapy suggesting lower activation and migration to the skin of activated T 
cells. The study was also made to potentially identify biomarkers that could be used to predict 
patients‘ responsiveness to NB-UVB phototherapy. The results suggest that FLG genotype and 
plasma concentration of 25 (OH) vitamin D and nitrate could not be used as biomarkers to predict 
clinical efficacy of NB-UVB phototherapy.  
 
Considering the sample size in this study, further studies with larger number of participants 
will be required to confirm the conclusion that FLG mutations do not affect clinical efficacy 
of NB-UVB phototherapy. Besides, in order to further determine the effect of FLG mutations 
on the clinical efficacy of NB-UVB phototherapy, AD patients with and without FLG null 
mutations receiving same dose of NB-UVB irradiation are needed. Lastly, further study 
investigating the correlation between the presence of Foxp3+Tregs locally in the skin before vs after 
NB-UVB phototherapy and cutaneous concentration of nitrate/nitrite will provide more information 
of the mechanisms contributing to the clinical efficacy of NB-UVB phototherapy. 
 
Overall, the study has elucidated the key cellular effects of UV irradiation induced anti-inflammatory 
molecules NO and cis-UCA on the generation of Tregs which will be of importance when 
























Appendix I Patients information sheet for the clinical study 
        
       
Department of Dermatology 
Lauriston Building 
Lauriston Place 
Edinburgh EH3 9HA 
 




You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what will be involved. Please take time 
to read the following information sheet carefully and discuss it with others if you wish. Ask 
us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you would like to take part in the study. All the information collected 
about you during the course of the research will be kept strictly confidential. Your General 
Practitioner will be informed of your participation in this study, provided that you are in 
agreement with this. 
 
What is the purpose of the study? 
Atopic dermatitis (AD)/Eczema is one of the most common skin conditions and affects more 
than 1 in 5 people in the UK. It is a condition causing a red, itchy rash. The exact cause of 
eczema is poorly understood, and we are carrying out research on this. In about 80% of  
eczema patients, natural sunlight or artificial sunlight makes their skin improve.  How well 
and how quickly patients respond can vary and we wish to study why this is.  Interleukin 22 is 
a substance that is produced by immune cells. Patients with high levels of this substance in 
their blood typically have worse eczema than those with low levels. It is thought that 




reducing levels of Interleukin-22.  We wish to study how treatment with artificial sunlight 
(phototherapy) affects levels of Interleukin-22 in eczema patients. 
 
Why have I been invited? 
You are on the waiting list for ultraviolet (phototherapy) or systemic treatment of your skin. 
 
Do I have to take part? 
No. It is entirely up to you to decide.  You have been sent a copy of this information sheet to 
read through, think and ask any questions before making a decision. If you do decide to take 
part you will be asked to sign a consent form and given a signed copy of the consent form to 
keep. If you decide to take part you are still free to withdraw at any time without giving a 
reason. A decision to withdraw or not to take part, will not affect the standard of care you 
receive. 
 
Will my taking part in the study be kept confidential? 
Yes, it will be kept confidential. All the information collected about you during the course of 
the research will be kept strictly confidential. Your General Practitioner will be informed of 
your participation in this study, provided that you are in agreement with this. 
 
What will happen to me if I take part? 
At your first treatment visit, the doctor running this study will ask if you would like to 
participate and answer any questions you might have concerning the study. You will be given 
a minimum of 24hours to consider it. If you are happy to be included in the study he or she 
will ask you to sign a consent form.  You will attend for treatment as normal (e.g. twice per 
week for phototherapy) and will receive study-specific measures at the beginning of treatment 
and following 8 weeks (i.e. there will be 2 research visits). The doctor will then examine your 
skin to assess the severity of your eczema.  The doctor will also take a 30 ml (about 6 
teaspoons) blood sample. We would also like to take 4 small samples (biopsies) of your skin 
at each visit. At each visit, 2 skin biopsies samples will be taken from skin affected by eczema 
and 2 samples will be taken from skin not affected by eczema. Four biopsies will be taken at 
each visit (with a total of  8 skin biopsies taken over the course of the studyAt each visit we 
would also like to take 10 small skin samples using a tape strips. A again these will be taken 
from normal and affected skin.  The doctor will ask you about your eczema and how you 
respond to sunlight. Each of the 2 visits will last around 1 hour.  
 
What are the possible disadvantages and risks of taking part? 




procedure. Occasionally people are left with a temporary bruise after blood is taken. The 
clinical scoring of your eczema will take about 10 minutes. Skin biopsies will be performed 
under local anaesthetic, which will require a small injection near the site of the biopsy. The 
injection of local anaesthetic before the biopsy often may sting. The biopsy sites will be 
closed with a suture (―stitch‖) to each site. The sites will heal over two to four weeks, and 
leave a small (3 to 4 mm) scar. there may be some discomfort while the biopsy heals. Sutures 
will be removed by Dr Weller or Dr Pappa. This will not require an additional visit to the 
clinic. Suture will be removed as part of a routine visit.  This almost invariably heals well, but 
there is a theoretical risk of keloid scarring, or poor scarring due to infection. Keloid scarring 
is extremely unusual in the forearm, where these studies will be carried out. The biopsies will 
be undertaken using aseptic technique, so that the risk of wound infection is very low.  
 
Tape stripping involves pressing a strip of sellotape like tape onto the skin and pulling it off, 
to remove some surface skin cells Tape stripping is painless and leaves no marks. There will 
be no alteration in the phototherapy treatment of your eczema.  
 
What are the possible benefits of taking part? 
None personally, but the research we are undertaking should help the understanding of 
eczema and we hope will lead to better treatments for all in future. 
 
What will happen to my blood and skin tissues? 
We wish to analyse your blood and skin samples to measure levels substances associated with 
eczema to see how these change following treatment. Some of these tests will involve DNA 
analysis of your blood.  
This will be fully anonymised, so that DNA analysis results cannot connected to you.  
 
We would like to keep any remaining samples to use in future studies.  
 
If you lose the capacity to give consent, you would be withdrawn from the study. In these 
circumstances, we would like to keep any data or tissue we have already collected. However, 
no further data or tissue would be collected.  
 
Who will see my records and know about my taking part? 
If you consent to take part in the research your medical records may be inspected by the 
regulatory authorities to check that the study is being carried out correctly. Your name will not 
be disclosed outside the clinic or appear on any reports or publications resulting from the 




taken part in this research study. 
 
The data generated from this research will be stored on a password protected computer and 
will be anonymous, with no indication of the identity of individuals involved. The data will 
be kept for 5 years or until published in the scientific literature (whichever is the sooner). 
 
What will happen to the results of the research study? 
The study may be published in a scientific journal, usually within three years after completion 
of the study. If results are published, this will be done without revealing your identity, which 
will remain confidential. 
 
Who is organising the study? 
The research study is being conducted by doctors at the University of Edinburgh 
Dermatology department. Your doctor will receive no personal payment. 
 
Who has reviewed this study? 
The study was approved by the NRES Committee North West - Preston. 
 
If you need any more information about this study please contact:  
 
Dr Richard Weller 0131-536-3229 or r.weller@ed.ac.uk   
 
If you would like to discuss this study with someone independent of the study team please 
contact:  Professor Jonathan Rees on:  (0131 536 2041) or email: k.muir@ed.ac.uk  
 
If you wish to make a complaint about the study please contact NHS Lothian: 
 
NHS Lothian Complaints Team 
2nd Floor 
Waverley Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
  
Thank you for taking time to read this information. If you decide to take part in the research 
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